
{ "head": { "link": [], "vars": ["drug", "transform", "mass"] },
  "results": { "distinct": false, "ordered": true, "bindings": [
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00118" }	, "transform": { "type": "literal", "value": "Significant first-pass metabolism in the liver. Approximately 50% of S-Adenosylmethionine (SAMe) is metabolized in the liver. SAMe is metabolized to S-adenosylhomocysteine, which is then metabolized to homocysteine. Homocysteine can either be metabolized to cystathionine and then cysteine or to methionine. The cofactor in the metabolism of homocysteine to cysteine is vitamin B6. Cofactors for the metabolism of homocysteine to methionine are folic acid, vitamin B12 and betaine." }	, "mass": { "type": "literal", "value": "398.1372" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00119" }	, "transform": { "type": "literal", "value": "In the liver, pyruvate is metabolized via several pathways." }	, "mass": { "type": "literal", "value": "88.016" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00120" }	, "transform": { "type": "literal", "value": "Hepatic. L-phenylalanine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body, where it undergoes metabolic reactions similar to those that take place in the liver." }	, "mass": { "type": "literal", "value": "165.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00123" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "146.1055" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00125" }	, "transform": { "type": "literal", "value": "Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized." }	, "mass": { "type": "literal", "value": "174.1117" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00126" }	, "transform": { "type": "literal", "value": "Hepatic. Ascorbic acid is reversibly oxidised (by removal of the hydrogen from the enediol group of ascorbic acid) to dehydroascorbic acid. The two forms found in body fluids are physiologically active. Some ascorbic acid is metabolized to inactive compounds including ascorbic acid-2-sulfate and oxalic acid." }	, "mass": { "type": "literal", "value": "176.0321" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00129" }	, "transform": { "type": "literal", "value": "Ornithine undergoes extensive metabolism in the liver to L-arginine, polyamines, and proline, and several other metabolites." }	, "mass": { "type": "literal", "value": "132.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00130" }	, "transform": { "type": "literal", "value": "Enterocytes, Hepatic" }	, "mass": { "type": "literal", "value": "146.0691" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00134" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "149.051" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00135" }	, "transform": { "type": "literal", "value": "In the liver, L-tyrosine is involved in a number of biochemical reactions, including protein synthesis and oxidative catabolic reactions. L-tyrosine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body." }	, "mass": { "type": "literal", "value": "181.0739" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00141" }	, "transform": { "type": "literal", "value": "A significant fraction of ingested glucosamine is catabolized by first-pass metabolism in the liver." }	, "mass": { "type": "literal", "value": "221.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00142" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "147.0532" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00145" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "75.032" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00150" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "204.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00156" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "119.0582" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00161" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "117.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00172" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "115.0633" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03501" }	, "mass": { "type": "literal", "value": "566.055" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00114" }	, "mass": { "type": "literal", "value": "247.0246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00116" }	, "mass": { "type": "literal", "value": "445.171" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00117" }	, "mass": { "type": "literal", "value": "155.0695" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00121" }	, "mass": { "type": "literal", "value": "244.0882" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00122" }	, "mass": { "type": "literal", "value": "104.1075" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00128" }	, "mass": { "type": "literal", "value": "133.0375" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00131" }	, "mass": { "type": "literal", "value": "347.0631" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00133" }	, "mass": { "type": "literal", "value": "105.0426" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00139" }	, "mass": { "type": "literal", "value": "118.0266" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00143" }	, "mass": { "type": "literal", "value": "307.0838" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00149" }	, "mass": { "type": "literal", "value": "131.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00151" }	, "mass": { "type": "literal", "value": "121.0197" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00160" }	, "mass": { "type": "literal", "value": "89.0477" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00171" }	, "mass": { "type": "literal", "value": "506.9957" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00173" }	, "mass": { "type": "literal", "value": "135.0545" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00174" }	, "mass": { "type": "literal", "value": "132.0535" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00677" }	, "mass": { "type": "literal", "value": "184.0665" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01592" }	, "mass": { "type": "literal", "value": "55.9349" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00140" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "376.1383" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00152" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "265.1123" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00165" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "169.0739" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00167" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "131.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00396" }	, "transform": { "type": "literal", "value": "Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones." }	, "mass": { "type": "literal", "value": "314.2246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00583" }	, "transform": { "type": "literal", "value": "Major metabolites include trimethylamine N-oxide and [3H]-gamma-butyrobetaine." }	, "mass": { "type": "literal", "value": "161.1052" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00627" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "123.032" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00640" }	, "transform": { "type": "literal", "value": "Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol." }	, "mass": { "type": "literal", "value": "267.0968" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00655" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "270.162" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00742" }	, "transform": { "type": "literal", "value": "Mannitol is metabolized only slightly, if at all, to glycogen in the liver." }	, "mass": { "type": "literal", "value": "182.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00855" }	, "transform": { "type": "literal", "value": "Following topical administration, synthesis into protoporphyrin IX takes place in situ in the skin." }	, "mass": { "type": "literal", "value": "131.0582" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00898" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1." }	, "mass": { "type": "literal", "value": "46.0419" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01235" }	, "transform": { "type": "literal", "value": "95% of an administered oral dose of levodopa is pre-systemically decarboxylated to dopamine by the L-aromatic amino acid decarboxylase (AAAD) enzyme in the stomach, lumen of the intestine, kidney, and liver. Levodopa also may be methoxylated by the hepatic catechol-O-methyltransferase (COMT) enzyme system to 3-O-methyldopa (3-OMD), which cannot be converted to central dopamine." }	, "mass": { "type": "literal", "value": "197.0688" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00148" }	, "mass": { "type": "literal", "value": "131.0695" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00155" }	, "mass": { "type": "literal", "value": "175.0957" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00360" }	, "mass": { "type": "literal", "value": "241.1175" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00825" }	, "mass": { "type": "literal", "value": "156.1514" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00158" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "441.1397" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00184" }	, "transform": { "type": "literal", "value": "Primarily hepatic, cotinine is the primary metabolite." }	, "mass": { "type": "literal", "value": "162.1157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00435" }	, "transform": { "type": "literal", "value": "via pulmonary capillary bed" }	, "mass": { "type": "literal", "value": "29.998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00624" }	, "transform": { "type": "literal", "value": "Testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT)." }	, "mass": { "type": "literal", "value": "288.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00668" }	, "transform": { "type": "literal", "value": "Epinephrine is rapidly inactivated in the body and is degraded by enzymes in the liver and other tissues. The larger portion of injected doses is excreted in the urine as inactivated compounds and the remainder either partly unchanged or conjugated. The drug becomes fixed in the tissues and is inactivated chiefly by enzymatic transformation to metanephrine or normetanephrine either of which is subsequently conjugated and excreted in the urine in the form of sulfates and glucuronides. Either sequence results in the formation of 3-methoxy-4-hydroxy-mandelic acid which also is detectable in the urine." }	, "mass": { "type": "literal", "value": "183.0895" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00741" }	, "transform": { "type": "literal", "value": "Primarily hepatic via CYP3A4" }	, "mass": { "type": "literal", "value": "362.2093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00755" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "300.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00917" }	, "transform": { "type": "literal", "value": "Rapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys." }	, "mass": { "type": "literal", "value": "352.225" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00127" }	, "mass": { "type": "literal", "value": "202.2157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00138" }	, "mass": { "type": "literal", "value": "240.0238" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00166" }	, "mass": { "type": "literal", "value": "206.0435" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00368" }	, "mass": { "type": "literal", "value": "169.0739" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00936" }	, "mass": { "type": "literal", "value": "138.0317" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02527" }	, "mass": { "type": "literal", "value": "329.0525" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00783" }	, "transform": { "type": "literal", "value": "Exogenous estrogens are metabolized using the same mechanism as endogenous estrogens. Estrogens are partially metabolized by cytochrome P450." }	, "mass": { "type": "literal", "value": "272.1776" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01440" }	, "mass": { "type": "literal", "value": "104.0473" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00146" }	, "transform": { "type": "literal", "value": "Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3." }	, "mass": { "type": "literal", "value": "400.3341" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00276" }	, "transform": { "type": "literal", "value": "Extensive, primarily hepatic, converted to glutathione conjugate." }	, "mass": { "type": "literal", "value": "393.1147" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00295" }	, "transform": { "type": "literal", "value": "Primarily hepatic (90%), converted to dihydromorphinone and normorphine. Also converted to morphine-3-glucuronide (M3G) and morphine-6-glucuronide. Virtually all morphine is converted to glucuronide metabolites; only a small fraction (less than 5%) of absorbed morphine is demethylated." }	, "mass": { "type": "literal", "value": "285.1365" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00382" }	, "transform": { "type": "literal", "value": "Hepatic. Cytochrome P450 1A2 is the principal isozyme involved in tacrine metabolism. The major metabolite, 1-hydroxy-tacrine (velnacrine), has central cholinergic activity." }	, "mass": { "type": "literal", "value": "198.1157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00572" }	, "transform": { "type": "literal", "value": "Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver. From 13 to 50% is excreted unchanged in the urine." }	, "mass": { "type": "literal", "value": "289.1678" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00605" }	, "transform": { "type": "literal", "value": "Undergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Available evidence indicates that the biological activity resides with the sulfide metabolite." }	, "mass": { "type": "literal", "value": "356.0882" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00773" }	, "transform": { "type": "literal", "value": "Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine." }	, "mass": { "type": "literal", "value": "588.1843" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00907" }	, "transform": { "type": "literal", "value": "Hepatic. Cocaine is metabolized to benzoylecgonine and ecgonine methyl ester, which are both excreted in the urine. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself." }	, "mass": { "type": "literal", "value": "303.1471" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00945" }	, "transform": { "type": "literal", "value": "Aspirin is rapidly hydrolyzed primarily in the liver to salicylic acid, which is conjugated with glycine (forming salicyluric acid) and glucuronic acid and excreted largely in the urine." }	, "mass": { "type": "literal", "value": "180.0423" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01240" }	, "transform": { "type": "literal", "value": "Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1&alpha; (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1&alpha; (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans." }	, "mass": { "type": "literal", "value": "352.225" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03193" }	, "mass": { "type": "literal", "value": "284.2715" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04827" }	, "mass": { "type": "literal", "value": "89.0477" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01092" }	, "mass": { "type": "literal", "value": "584.2833" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00136" }	, "transform": { "type": "literal", "value": "The first pathway involves 24-hydroxylase activity in the kidney; this enzyme is also present in many target tissues which possess the vitamin D receptor such as the intestine. The end product of this pathway is a side chain shortened metabolite, calcitroic acid. The second pathway involves the conversion of calcitriol via the stepwise hydroxylation of carbon-26 and carbon-23, and cyclization to yield ultimately 1a,25R(OH)2-26,23S-lactone D3. The lactone appears to be the major metabolite circulating in humans." }	, "mass": { "type": "literal", "value": "416.329" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00328" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "357.0768" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00424" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "289.1678" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00451" }	, "transform": { "type": "literal", "value": "Hepatic (primarily via cytochrome P450 isozyme 3A4)." }	, "mass": { "type": "literal", "value": "776.6867" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "375.1401" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00563" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "454.1713" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00586" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "295.0167" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00694" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "527.1791" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00822" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "296.0509" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00861" }	, "transform": { "type": "literal", "value": "Hepatic, primarily via glucuronide conjugation (90% of administered dose)." }	, "mass": { "type": "literal", "value": "250.0442" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01050" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "206.1307" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01065" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized in the liver by hydroxylation to 6-hydroxymelatonin." }	, "mass": { "type": "literal", "value": "232.1212" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03615" }	, "mass": { "type": "literal", "value": "454.2275" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04630" }	, "mass": { "type": "literal", "value": "360.1937" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00553" }	, "mass": { "type": "literal", "value": "216.0423" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00847" }	, "mass": { "type": "literal", "value": "77.0299" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00997" }	, "mass": { "type": "literal", "value": "543.1741" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01009" }	, "mass": { "type": "literal", "value": "254.0943" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01022" }	, "mass": { "type": "literal", "value": "450.3498" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01094" }	, "mass": { "type": "literal", "value": "302.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00163" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "430.3811" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00513" }	, "transform": { "type": "literal", "value": "Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid." }	, "mass": { "type": "literal", "value": "131.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00894" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized to several derivatives in the liver, all of which preserve the lactone D-ring." }	, "mass": { "type": "literal", "value": "300.1725" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01033" }	, "transform": { "type": "literal", "value": "Hepatic. Degradation primarily by xanthine oxidase. The catabolism of mercaptopurine and its metabolites is complex. In humans, after oral administration of <sup>35</sup>S-6-mercaptopurine, urine contains intact mercaptopurine, thiouric acid (formed by direct oxidation by xanthine oxidase, probably via 6-mercapto-8-hydroxypurine), and a number of 6-methylated thiopurines. The methylthiopurines yield appreciable amounts of inorganic sulfate." }	, "mass": { "type": "literal", "value": "152.0157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00279" }	, "mass": { "type": "literal", "value": "650.79" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00115" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "1354.5674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00852" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "165.1154" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00987" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "243.0855" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02709" }	, "transform": { "type": "literal", "value": "Hepatic. Rapidly metabolized and excreted." }	, "mass": { "type": "literal", "value": "228.0786" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00988" }	, "transform": { "type": "literal", "value": "Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA)." }	, "mass": { "type": "literal", "value": "153.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01686" }	, "mass": { "type": "literal", "value": "202.143" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02901" }	, "mass": { "type": "literal", "value": "290.2246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00153" }	, "transform": { "type": "literal", "value": "Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2." }	, "mass": { "type": "literal", "value": "396.3392" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00169" }	, "transform": { "type": "literal", "value": "Within the liver, cholecalciferal is hydroxylated to calcidiol (25-hydroxycholecalciferol) by the enzyme 25-hydroxylase. Within the kidney, calcidiol serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3." }	, "mass": { "type": "literal", "value": "384.3392" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00170" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "172.0524" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00717" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "298.1933" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00770" }	, "transform": { "type": "literal", "value": "Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by beta- and omega-oxidation." }	, "mass": { "type": "literal", "value": "354.2406" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04573" }	, "mass": { "type": "literal", "value": "288.1725" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01055" }	, "mass": { "type": "literal", "value": "198.0641" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00318" }	, "transform": { "type": "literal", "value": "Hepatic. Codeine is a prodrug, itself inactive, but demethylated to the active morphine by the liver enzyme CYP2D6." }	, "mass": { "type": "literal", "value": "299.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01698" }	, "mass": { "type": "literal", "value": "610.1534" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00468" }	, "transform": { "type": "literal", "value": "Hepatic, over 80% metabolized by the liver." }	, "mass": { "type": "literal", "value": "324.1838" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00981" }	, "transform": { "type": "literal", "value": "Quickly hydrolyzed by cholinesterases" }	, "mass": { "type": "literal", "value": "275.1634" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01452" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "369.1576" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00132" }	, "mass": { "type": "literal", "value": "278.2246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00159" }	, "mass": { "type": "literal", "value": "302.2246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00206" }	, "mass": { "type": "literal", "value": "608.2734" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00908" }	, "mass": { "type": "literal", "value": "324.1838" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01089" }	, "mass": { "type": "literal", "value": "578.2628" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01180" }	, "mass": { "type": "literal", "value": "634.289" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01426" }	, "mass": { "type": "literal", "value": "326.1994" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01645" }	, "mass": { "type": "literal", "value": "270.0528" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06151" }	, "transform": { "type": "literal", "value": "Hepatic. Deacetylated by the liver to cysteine and subsequently metabolized." }	, "mass": { "type": "literal", "value": "163.0303" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00180" }	, "transform": { "type": "literal", "value": "Primarily hepatic, converted to the S beta-OH metabolite." }	, "mass": { "type": "literal", "value": "434.2105" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00208" }	, "transform": { "type": "literal", "value": "Metabolized extensively by the liver; only trace amounts of intact drug are detected in the urine. At least 20 metabolites have been identified. It has been proposed that 1 or more active metabolites may account for ticlopidine's activity, because ticlopidine itself is an extremely weak platelet aggregation inhibitor in vitro at the concentrations achieved in vivo. However, no active metabolite has been identified." }	, "mass": { "type": "literal", "value": "263.0535" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00235" }	, "transform": { "type": "literal", "value": "There are five metabolites but the O-glucuronide represents the major pathway of biotransformation." }	, "mass": { "type": "literal", "value": "211.0746" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00277" }	, "transform": { "type": "literal", "value": "Hepatic. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity." }	, "mass": { "type": "literal", "value": "180.0647" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00280" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "339.2311" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "277.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00305" }	, "transform": { "type": "literal", "value": "Primarily hepatic, some in various other tissues." }	, "mass": { "type": "literal", "value": "334.1277" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00315" }	, "transform": { "type": "literal", "value": "Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite." }	, "mass": { "type": "literal", "value": "287.1634" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00316" }	, "transform": { "type": "literal", "value": "Approximately 90 to 95% of a dose is metabolized in the liver via the cytochrome P450 enzyme pathways (primarily by conjugation with glucuronic acid, sulfuric acid, and cysteine). An intermediate metabolite is hepatotoxic and most likely nephrotoxic and can accumulate after the primary metabolic pathways have been saturated." }	, "mass": { "type": "literal", "value": "151.0633" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00321" }	, "transform": { "type": "literal", "value": "Exclusively hepatic, with first pass effect. Amitriptyline is demethylated in the liver to its primary active metabolite, nortriptyline." }	, "mass": { "type": "literal", "value": "277.1831" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00327" }	, "transform": { "type": "literal", "value": "Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide." }	, "mass": { "type": "literal", "value": "285.1365" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00331" }	, "transform": { "type": "literal", "value": "Metformin is not metabolized." }	, "mass": { "type": "literal", "value": "129.1014" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00332" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "332.2226" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00351" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified." }	, "mass": { "type": "literal", "value": "342.2195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "326.1298" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00373" }	, "transform": { "type": "literal", "value": "Primarily hepatic (80%) via the cytochrome P450 2D6 isoenzyme." }	, "mass": { "type": "literal", "value": "316.1569" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00394" }	, "transform": { "type": "literal", "value": "Metabolism mediated via esterase enzymes that are found in most tissues. Undergoes rapid and extensive conversion to beclomenthasone-17-monopropionate (17-BMP) during absorption" }	, "mass": { "type": "literal", "value": "408.1704" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404" }	, "transform": { "type": "literal", "value": "Hepatic. Hydroxylated in the liver to &alpha;-hydroxyalprazolam, which is also active. This and other metabolites are later excreted in urine as glucuronides." }	, "mass": { "type": "literal", "value": "308.0829" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00408" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "327.1138" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00414" }	, "transform": { "type": "literal", "value": "Extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects." }	, "mass": { "type": "literal", "value": "324.1144" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00422" }	, "transform": { "type": "literal", "value": "Hepatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (&alpha;-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity." }	, "mass": { "type": "literal", "value": "233.1416" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00458" }	, "transform": { "type": "literal", "value": "Exclusively hepatic. Imipramine is converted in the liver to desipramine and 2-hydroxydesipramine, both active metabolites." }	, "mass": { "type": "literal", "value": "280.1939" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00481" }	, "transform": { "type": "literal", "value": "Hepatic, raloxifene undergoes extensive first-pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4'-diglucuronide. No other metabolites have been detected, providing strong evidence that raloxifene is not metabolized by cytochrome P450 pathways" }	, "mass": { "type": "literal", "value": "473.1661" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00490" }	, "transform": { "type": "literal", "value": "Metabolized hepatically, primarily by oxidation by cytochrome P450 3A4 producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP)" }	, "mass": { "type": "literal", "value": "385.2478" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00514" }	, "transform": { "type": "literal", "value": "Hepatic. Rapidly and extensively metabolized to dextrorphan (active metabolite). One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6." }	, "mass": { "type": "literal", "value": "271.1936" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00517" }	, "transform": { "type": "literal", "value": "Hepatic, by enzymatic hydrolysis." }	, "mass": { "type": "literal", "value": "361.1616" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00521" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "292.1787" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00541" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "824.3996" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00542" }	, "transform": { "type": "literal", "value": "Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat." }	, "mass": { "type": "literal", "value": "424.1998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "575.209" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00557" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "374.1761" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00570" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes." }	, "mass": { "type": "literal", "value": "810.4204" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00590" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "451.1856" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00598" }	, "transform": { "type": "literal", "value": "Primarily hepatic, undergoes significant first pass metabolism" }	, "mass": { "type": "literal", "value": "328.1787" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00603" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "344.2351" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00610" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "167.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00612" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "325.2253" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00636" }	, "transform": { "type": "literal", "value": "Hepatic and gastrointestinal: rapid de-esterification occurs in the gastrointestinal tract and/or on first-pass metabolism to produce the active form, clofibric acid (chlorophenoxy isobutyric acid [CPIB])." }	, "mass": { "type": "literal", "value": "242.071" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00656" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "371.1513" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675" }	, "transform": { "type": "literal", "value": "Hepatic. Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in plasma. N-desmethyl tamoxifen activity is similar to tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P450 CYP3A4, CYP2C9 and CYP2D6, and an inhibitor of P-glycoprotein." }	, "mass": { "type": "literal", "value": "371.2249" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00678" }	, "transform": { "type": "literal", "value": "Hepatic. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan." }	, "mass": { "type": "literal", "value": "422.1622" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00687" }	, "transform": { "type": "literal", "value": "Hepatic, some renal." }	, "mass": { "type": "literal", "value": "380.1999" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00706" }	, "transform": { "type": "literal", "value": "Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established." }	, "mass": { "type": "literal", "value": "408.1719" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00746" }	, "transform": { "type": "literal", "value": "Deferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism." }	, "mass": { "type": "literal", "value": "560.3534" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00829" }	, "transform": { "type": "literal", "value": "Hepatic via the Cytochrome P450 enzyme system. The main active metabolite is desmethyldiazepam, in addition to minor active metabolites including temazepam and oxazepam." }	, "mass": { "type": "literal", "value": "284.0716" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00882" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "405.1859" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00888" }	, "transform": { "type": "literal", "value": "Undergoes rapid chemical transformation and combines with water or reactive compounds of cells, so that the drug is no longer present in active form a few minutes after administration." }	, "mass": { "type": "literal", "value": "155.0269" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00915" }	, "transform": { "type": "literal", "value": "No appreciable metabolism, although negligible amounts of an acetyl metabolite have been identified." }	, "mass": { "type": "literal", "value": "151.1361" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01005" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "76.0273" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01011" }	, "transform": { "type": "literal", "value": "Hepatic. The major biotransformation is reduction of the ketone to metyrapol, an active alcohol metabolite. Metyrapone and metyrapol are both conjugated with glucuronide." }	, "mass": { "type": "literal", "value": "226.1106" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01016" }	, "transform": { "type": "literal", "value": "Primarily hepatic (mainly cytochrome P450 3A4). The major metabolite is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites contribute no significant hypoglycemic action in humans as they are only weakly active." }	, "mass": { "type": "literal", "value": "493.1438" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076" }	, "transform": { "type": "literal", "value": "Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites." }	, "mass": { "type": "literal", "value": "558.253" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "411.1846" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "305.0738" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118" }	, "transform": { "type": "literal", "value": "Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone." }	, "mass": { "type": "literal", "value": "645.0237" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01119" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "229.9917" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01124" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "270.1038" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01136" }	, "transform": { "type": "literal", "value": "Hepatic. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. Demethylation and hydroxylation at the phenol ring produce three active metabolites with b-receptor blocking activity. The 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for b-blockade." }	, "mass": { "type": "literal", "value": "406.1893" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01142" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "279.1623" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01143" }	, "transform": { "type": "literal", "value": "Amifostine is rapidly dephosphorylated by alkaline phosphatase in tissues primarily to the active free thiol metabolite and, subsequently, to a less active disulfide metabolite." }	, "mass": { "type": "literal", "value": "214.0541" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01151" }	, "transform": { "type": "literal", "value": "Desipramine is extensively metabolized in the liver and is cleared mainly by 2-hydroxylation and glucuronidation, whereas 10-hydroxylation is of minor importance. The 2-hydroxylation metabolic pathway of desipramine is under genetic control." }	, "mass": { "type": "literal", "value": "266.1783" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156" }	, "transform": { "type": "literal", "value": "Reduction of the carbonyl groupand/or hydroxylation of the tert-butyl group of bupropion." }	, "mass": { "type": "literal", "value": "239.1077" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01162" }	, "transform": { "type": "literal", "value": "Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity." }	, "mass": { "type": "literal", "value": "387.1907" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01176" }	, "transform": { "type": "literal", "value": "Cyclizine is metabolised to its N-demethylated derivative, norcyclizine, which has little antihistaminic (H1) activity compared to Cyclizine." }	, "mass": { "type": "literal", "value": "266.1783" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01193" }	, "transform": { "type": "literal", "value": "Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol)." }	, "mass": { "type": "literal", "value": "336.2049" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01242" }	, "transform": { "type": "literal", "value": "Hepatic. The main active metabolite is desmethylclomipramine." }	, "mass": { "type": "literal", "value": "314.155" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01396" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "764.4347" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01403" }	, "transform": { "type": "literal", "value": "Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety." }	, "mass": { "type": "literal", "value": "328.1609" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01577" }	, "transform": { "type": "literal", "value": "Hepatic. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine." }	, "mass": { "type": "literal", "value": "149.1204" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00284" }	, "mass": { "type": "literal", "value": "645.248" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00372" }	, "mass": { "type": "literal", "value": "399.1803" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477" }	, "mass": { "type": "literal", "value": "318.0957" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00515" }	, "mass": { "type": "literal", "value": "298.9556" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00797" }	, "mass": { "type": "literal", "value": "160.1" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00819" }	, "mass": { "type": "literal", "value": "221.9881" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00831" }	, "mass": { "type": "literal", "value": "407.1643" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01003" }	, "mass": { "type": "literal", "value": "468.0693" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01037" }	, "mass": { "type": "literal", "value": "187.1361" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01063" }	, "mass": { "type": "literal", "value": "411.198" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01064" }	, "mass": { "type": "literal", "value": "211.1208" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01070" }	, "mass": { "type": "literal", "value": "398.3549" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01200" }	, "mass": { "type": "literal", "value": "653.2213" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01231" }	, "mass": { "type": "literal", "value": "309.2093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04575" }	, "transform": { "type": "literal", "value": "Metabolized principally to the parent compound, ethinyl estradiol. Ethinyl estradiol is metabolized in the liver. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens." }	, "mass": { "type": "literal", "value": "364.2402" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04829" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "323.1998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06144" }	, "transform": { "type": "literal", "value": "Hepatic. Sertindole is metabolized by cytochrome P450 isoenzymes CYP 2D6 and CYP 3A4." }	, "mass": { "type": "literal", "value": "440.1779" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "318.1555" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00182" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "135.1048" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00191" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "149.1204" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00201" }	, "transform": { "type": "literal", "value": "Hepatic cytochrome P450 1A2 (CYP 1A2) is involved in caffeine biotransformation. About 80% of a dose of caffeine is metabolized to paraxanthine (1,7-dimethylxanthine), 10% to theobromine (3,7-dimethylxanthine), and 4% to theophylline (1,3-dimethylxanthine)." }	, "mass": { "type": "literal", "value": "194.0804" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00202" }	, "transform": { "type": "literal", "value": "By pseudocholinesterase, to succinylmonocholine and choline." }	, "mass": { "type": "literal", "value": "290.2206" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00204" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "441.1392" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "324.1638" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00222" }	, "transform": { "type": "literal", "value": "Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear." }	, "mass": { "type": "literal", "value": "490.225" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00228" }	, "transform": { "type": "literal", "value": "2.4% of the dose is slowly metabolized hepatically via oxidation and dehalogenation (primarily through the actions of cytochrome P450 2E1). Leads to low levels of serum fluoride (15 &micro;mol/L)." }	, "mass": { "type": "literal", "value": "183.9714" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "412.1125" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00255" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "268.1463" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00268" }	, "transform": { "type": "literal", "value": "Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%)." }	, "mass": { "type": "literal", "value": "260.1889" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00304" }	, "transform": { "type": "literal", "value": "Desogestrel is rapidly and completely metabolized by hydroxylation in the intestinal mucosa and on first pass through the liver to etonogestrel. Other metabolites (i.e., 3a-OH-desogestrel, 3b-OH-desogestrel, and 3a-OH-5a-H-desogestrel) with no pharmacologic actions also have been identified and these metabolites may undergo glucuronide and sulfate conjugation." }	, "mass": { "type": "literal", "value": "310.2297" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00312" }	, "transform": { "type": "literal", "value": "by hepatic microsomal enzyme system" }	, "mass": { "type": "literal", "value": "226.1317" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00325" }	, "transform": { "type": "literal", "value": "Metabolized by reaction with hemoglobin to produce cyanmethemoglobin and cynide ions" }	, "mass": { "type": "literal", "value": "215.9483" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "312.1409" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00338" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "345.1147" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00354" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "432.2332" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00388" }	, "transform": { "type": "literal", "value": "Oral phenylephrine is extensively metabolised by monoamine oxidase, an enzyme which is present in the stomach and liver." }	, "mass": { "type": "literal", "value": "167.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00420" }	, "transform": { "type": "literal", "value": "Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide." }	, "mass": { "type": "literal", "value": "284.1347" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00421" }	, "transform": { "type": "literal", "value": "Rapidly and extensively metabolized. The metabolic pathway of spironolactone is complex and can be divided into two main routes: those in which the sulfur moiety is retained and those in which the sulfur moiety is removed by dethioacetylation. Spironolactone is transformed to a reactive metabolite that can inactivate adrenal and testicular cytochrome P450 enzymes. It also has anti-androgenic activity." }	, "mass": { "type": "literal", "value": "416.2021" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00428" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "265.091" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00433" }	, "transform": { "type": "literal", "value": "Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4." }	, "mass": { "type": "literal", "value": "373.1379" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00457" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline)." }	, "mass": { "type": "literal", "value": "383.1594" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "585.2104" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482" }	, "transform": { "type": "literal", "value": "Hepatic. Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors." }	, "mass": { "type": "literal", "value": "381.0759" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00484" }	, "transform": { "type": "literal", "value": "Metabolized primarily by the liver." }	, "mass": { "type": "literal", "value": "291.012" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00494" }	, "transform": { "type": "literal", "value": "Metabolized via isomerization to the cis-isomer, followed by direct glucuronidation of the parent and cis-isomer." }	, "mass": { "type": "literal", "value": "305.1012" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00497" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "315.1471" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00498" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "222.0681" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00499" }	, "transform": { "type": "literal", "value": "Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration." }	, "mass": { "type": "literal", "value": "276.0722" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00533" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolism of rofecoxib is primarily mediated through reduction by cytosolic enzymes. The principal metabolic products are the cis-dihydro and trans-dihydro derivatives of rofecoxib, which account for nearly 56% of recovered radioactivity in the urine. An additional 8.8% of the dose was recovered as the glucuronide of the hydroxy derivative, a product of oxidative metabolism. The biotransformation of rofecoxib and this metabolite is reversible in humans to a limited extent (&lt; 5%). These metabolites are inactive as COX-1 or COX-2 inhibitors. Cytochrome P450 plays a minor role in metabolism of rofecoxib." }	, "mass": { "type": "literal", "value": "314.0613" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00540" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "263.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00544" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "130.0179" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00571" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "259.1572" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00630" }	, "transform": { "type": "literal", "value": "There is no evidence that alendronate is metabolized in humans or animals." }	, "mass": { "type": "literal", "value": "249.0167" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00633" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "200.1313" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00635" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "358.178" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00669" }	, "transform": { "type": "literal", "value": "Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme." }	, "mass": { "type": "literal", "value": "295.1354" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00696" }	, "transform": { "type": "literal", "value": "Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile." }	, "mass": { "type": "literal", "value": "581.2638" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "329.1427" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00716" }	, "transform": { "type": "literal", "value": "Nedocromil is not metabolized after IV administration and is excreted unchanged." }	, "mass": { "type": "literal", "value": "371.1005" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00727" }	, "transform": { "type": "literal", "value": "Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation" }	, "mass": { "type": "literal", "value": "227.0026" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00733" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "137.0715" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00753" }	, "transform": { "type": "literal", "value": "Minimal" }	, "mass": { "type": "literal", "value": "183.9714" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00764" }	, "transform": { "type": "literal", "value": "Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6&szlig;-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4." }	, "mass": { "type": "literal", "value": "426.1365" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00775" }	, "transform": { "type": "literal", "value": "Metabolism appears to be limited." }	, "mass": { "type": "literal", "value": "440.2345" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00777" }	, "transform": { "type": "literal", "value": "Unknown, but most likely hepatic as with other phenothiazines." }	, "mass": { "type": "literal", "value": "340.1609" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00790" }	, "transform": { "type": "literal", "value": "Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine." }	, "mass": { "type": "literal", "value": "441.3203" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00796" }	, "transform": { "type": "literal", "value": "During absorption from the gastrointestinal tract, the prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan occurs by O -deethylation to form an inactive metabolite." }	, "mass": { "type": "literal", "value": "440.1597" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00818" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "178.1358" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00834" }	, "transform": { "type": "literal", "value": "Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17&ndash;propynyl chain." }	, "mass": { "type": "literal", "value": "429.2668" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00849" }	, "transform": { "type": "literal", "value": "Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours." }	, "mass": { "type": "literal", "value": "246.1004" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "403.1485" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00859" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "149.051" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00860" }	, "transform": { "type": "literal", "value": "Excreted in the urine as either free or glucoconjugate." }	, "mass": { "type": "literal", "value": "360.1937" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00876" }	, "transform": { "type": "literal", "value": "Eprosartan is not metabolized by the cytochrome P450 system. It is mainly eliminated as unchanged drug. Less than 2% of an oral dose is excreted in the urine as a glucuronide." }	, "mass": { "type": "literal", "value": "424.1457" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00881" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "438.2155" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00883" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "236.0281" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00890" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "266.1307" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00910" }	, "transform": { "type": "literal", "value": "Metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4" }	, "mass": { "type": "literal", "value": "416.329" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00952" }	, "transform": { "type": "literal", "value": "Primarily hepatic. <i>In vitro,</i> naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites." }	, "mass": { "type": "literal", "value": "335.1667" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00956" }	, "transform": { "type": "literal", "value": "Hepatic and also in intestinal mucosa." }	, "mass": { "type": "literal", "value": "299.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00960" }	, "transform": { "type": "literal", "value": "Hepatic. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates." }	, "mass": { "type": "literal", "value": "248.1525" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00966" }	, "transform": { "type": "literal", "value": "Minimally metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan." }	, "mass": { "type": "literal", "value": "514.2369" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00977" }	, "transform": { "type": "literal", "value": "Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens." }	, "mass": { "type": "literal", "value": "296.1776" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00984" }	, "transform": { "type": "literal", "value": "Nandrolone is unusual in that unlike most anabolic steroids, it is not broken down into the more reactive DHT by the enzyme 5\uFFFD\uFFFD-reductase, but rather into a less effective product known as Dihydronandrolone." }	, "mass": { "type": "literal", "value": "274.1933" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01029" }	, "transform": { "type": "literal", "value": "Hepatic. Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible." }	, "mass": { "type": "literal", "value": "428.2325" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01035" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "235.1685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01062" }	, "transform": { "type": "literal", "value": "Hepatic, primarily by CYP3A4" }	, "mass": { "type": "literal", "value": "357.2304" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01069" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "284.1347" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01097" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Leflunomide is converted to its active form following oral intake." }	, "mass": { "type": "literal", "value": "270.0616" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01100" }	, "transform": { "type": "literal", "value": "Notable first-pass metabolism in the liver, primarily by N-dealkylation via the cytochrome P450 isoenzymes CYP3A and CYP1A2 (and possibly CYP2D6). The activity of the two major metabolites has not been determined." }	, "mass": { "type": "literal", "value": "461.2279" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01115" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "346.1165" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "359.1304" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01132" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "356.1195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "469.2245" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01154" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "254.1089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01174" }	, "transform": { "type": "literal", "value": "Hepatic (mostly via CYP2C19)." }	, "mass": { "type": "literal", "value": "232.0848" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01183" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "327.1471" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01189" }	, "transform": { "type": "literal", "value": "Minimally biotransformed in the liver in humans (approximately 0.02% of the quantity absorbed)." }	, "mass": { "type": "literal", "value": "168.001" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01194" }	, "transform": { "type": "literal", "value": "Ophthalmic" }	, "mass": { "type": "literal", "value": "383.0643" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01205" }	, "transform": { "type": "literal", "value": "Hepatic. Flumazenil is completely (99%) metabolized. The major metabolites of flumazenil identified in urine are the de-ethylated free acid and its glucuronide conjugate." }	, "mass": { "type": "literal", "value": "303.1019" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01210" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "291.1834" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01213" }	, "transform": { "type": "literal", "value": "Primarily hepaticm the primary metabolite is 4-carboxypyrazole (approximately 80 to 85% of an administered dose). Other metabolites include 4-hydroxymethylpyrazole and the N -glucuronide conjugates of 4-carboxypyrazole and 4-hydroxymethylpyrazole." }	, "mass": { "type": "literal", "value": "82.0531" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224" }	, "transform": { "type": "literal", "value": "Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation. The major metabolites of quetiapine are inactive." }	, "mass": { "type": "literal", "value": "383.1667" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01227" }	, "transform": { "type": "literal", "value": "Levomethadyl acetate undergoes extensive first-pass metabolism to the active demethylated metabolite nor-levomethadyl acetate, which is further demethylated to a second active metabolite, dinor-levomethadyl acetate. These metabolites are more potent than the parent drug." }	, "mass": { "type": "literal", "value": "353.2355" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01229" }	, "transform": { "type": "literal", "value": "Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3&rsquo;-p-hydroxypaclitaxel and 6a, 3&rsquo;-p-dihydroxypaclitaxel, by CYP3A4." }	, "mass": { "type": "literal", "value": "853.331" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01239" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "315.0848" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01394" }	, "transform": { "type": "literal", "value": "Probably hepatic. Although colchicine metabolites have not been identified in humans, metabolism by mammalian hepatic microsomes has been demonstrated in vitro." }	, "mass": { "type": "literal", "value": "399.1682" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01576" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "135.1048" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01612" }	, "transform": { "type": "literal", "value": "Hepatic. The drug is metabolized rapidly, probably by hydrolytic denitration; approximately one-third of the inhaled amyl nitrite is excreted in the urine." }	, "mass": { "type": "literal", "value": "117.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03783" }	, "mass": { "type": "literal", "value": "179.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00237" }	, "mass": { "type": "literal", "value": "212.1161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00344" }	, "mass": { "type": "literal", "value": "263.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00387" }	, "mass": { "type": "literal", "value": "287.2249" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00505" }	, "mass": { "type": "literal", "value": "318.2797" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00550" }	, "mass": { "type": "literal", "value": "170.0514" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00670" }	, "mass": { "type": "literal", "value": "351.1695" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00842" }	, "mass": { "type": "literal", "value": "286.0509" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00844" }	, "mass": { "type": "literal", "value": "357.194" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01036" }	, "mass": { "type": "literal", "value": "325.2406" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01039" }	, "mass": { "type": "literal", "value": "360.1128" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01138" }	, "mass": { "type": "literal", "value": "404.1195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01159" }	, "mass": { "type": "literal", "value": "195.8902" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01586" }	, "mass": { "type": "literal", "value": "392.2927" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00200" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Cobalamins are absorbed in the ileum and stored in the liver. They continuously undergo enterohepatic recycling via secretion in the bile. Part of a dose is excreted in the urine, most of it in the first 8 hours." }	, "mass": { "type": "literal", "value": "1345.5671" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00506" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "312.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00539" }	, "transform": { "type": "literal", "value": "Hepatic. Mainly by CYP3A4." }	, "mass": { "type": "literal", "value": "405.1859" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00665" }	, "transform": { "type": "literal", "value": "The results of a human metabolism study using 14C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days." }	, "mass": { "type": "literal", "value": "317.0623" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01006" }	, "transform": { "type": "literal", "value": "Primarily hepatic via CYP3A4 and CYP2A6. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway." }	, "mass": { "type": "literal", "value": "285.1014" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01128" }	, "transform": { "type": "literal", "value": "Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation." }	, "mass": { "type": "literal", "value": "430.061" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01445" }	, "transform": { "type": "literal", "value": "Orally administered bufotenine undergoes extensive first-pass metabolism by the enzyme monoamine oxidase." }	, "mass": { "type": "literal", "value": "204.1263" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00137" }	, "mass": { "type": "literal", "value": "568.428" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00217" }	, "mass": { "type": "literal", "value": "388.0907" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00674" }	, "mass": { "type": "literal", "value": "287.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01392" }	, "transform": { "type": "literal", "value": "Yohimbine appears to undergo extensive metabolism in an organ of high flow such as the liver or kidney, however, the precise metabolic fate of yohimbine has not been fully determined." }	, "mass": { "type": "literal", "value": "354.1943" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00168" }	, "transform": { "type": "literal", "value": "Approximately 10% of aspartame (by weight) is broken down into methanol in the small intestine. Most of the methanol is absorbed and quickly converted into formaldehyde. Approximately 50% of aspartame (by weight) is broken down into phenylalanine. Approximately 40% of aspartame (by mass) is broken down into aspartic acid." }	, "mass": { "type": "literal", "value": "294.1216" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213" }	, "transform": { "type": "literal", "value": "Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity." }	, "mass": { "type": "literal", "value": "383.0751" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00928" }	, "transform": { "type": "literal", "value": "An in vitro study of azacitidine incubation in human liver fractions indicated that azacitidine may be metabolized by the liver. The potential of azacitidine to inhibit cytochrome P450 (CYP) enzymes is not known." }	, "mass": { "type": "literal", "value": "244.0808" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01093" }	, "transform": { "type": "literal", "value": "Dimethyl sulfoxide is metabolized in man by oxidation to dimethyl sulfone or by reduction in dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces." }	, "mass": { "type": "literal", "value": "78.0139" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01204" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "444.2009" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01355" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "236.1161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04819" }	, "mass": { "type": "literal", "value": "261.13" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04967" }	, "mass": { "type": "literal", "value": "340.1609" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00791" }	, "mass": { "type": "literal", "value": "251.0228" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00815" }	, "mass": { "type": "literal", "value": "288.1371" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01196" }	, "mass": { "type": "literal", "value": "439.1681" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01245" }	, "mass": { "type": "literal", "value": "258.3035" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01497" }	, "mass": { "type": "literal", "value": "411.241" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04840" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "175.1109" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00700" }	, "transform": { "type": "literal", "value": "Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma." }	, "mass": { "type": "literal", "value": "414.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00799" }	, "transform": { "type": "literal", "value": "Undergoes esterase hydrolysis in skin to form its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized in skin and, after systemic absorption, hepatically metabolized to sulfoxides, sulfones, and other polar products for elimination." }	, "mass": { "type": "literal", "value": "351.1293" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01101" }	, "transform": { "type": "literal", "value": "Metabolized by thymidine phosphorylase to fluoruracil." }	, "mass": { "type": "literal", "value": "359.1493" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "447.148" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04599" }	, "mass": { "type": "literal", "value": "219.0895" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04942" }	, "mass": { "type": "literal", "value": "351.1834" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00823" }	, "mass": { "type": "literal", "value": "384.2301" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01390" }	, "mass": { "type": "literal", "value": "83.9823" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00107" }	, "mass": { "type": "literal", "value": "1006.4365" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01541" }	, "mass": { "type": "literal", "value": "286.1933" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00091" }	, "transform": { "type": "literal", "value": "Hepatic, extensively metabolized." }	, "mass": { "type": "literal", "value": "1201.8414" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00115" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "1359.6065" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00178" }	, "transform": { "type": "literal", "value": "Hepatic. Ramipril is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes." }	, "mass": { "type": "literal", "value": "416.2311" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00181" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "213.0557" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00197" }	, "transform": { "type": "literal", "value": "A sulfate conjugate metabolite (Metabolite 1) and a quinone metabolite (Metabolite 3) have been detected in the plasma of healthy males. A glucuronide conjugate (Metabolite 2) has been detected in the urine and also in negligible amounts in the plasma. In healthy volunteers and in patients with type 2 diabetes, the steady-state concentration of Metabolite 1 is six to seven times that of troglitazone and Metabolite 3. In in vivo drug interaction studies, troglitazone has been shown to induce cytochrome P450 CYP3A4 at clinically relevant doses." }	, "mass": { "type": "literal", "value": "441.161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227" }	, "transform": { "type": "literal", "value": "hepatic" }	, "mass": { "type": "literal", "value": "404.2563" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00244" }	, "transform": { "type": "literal", "value": "Rapidly and extensively metabolized, mainly to N-acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal wall and the liver. Ac-5-ASA is further acetylated (deactivated) in at least 2 sites, the colonic epithelium and the liver." }	, "mass": { "type": "literal", "value": "153.0426" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00262" }	, "transform": { "type": "literal", "value": "Hepatic and rapid with active metabolites. Metabolites may persist in the plasma for several days." }	, "mass": { "type": "literal", "value": "213.0072" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00269" }	, "transform": { "type": "literal", "value": "Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated." }	, "mass": { "type": "literal", "value": "380.1179" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00281" }	, "transform": { "type": "literal", "value": "Primarily hepatic." }	, "mass": { "type": "literal", "value": "234.1732" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00286" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "372.1007" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00313" }	, "transform": { "type": "literal", "value": "Valproic Acid is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial &szlig;-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine." }	, "mass": { "type": "literal", "value": "144.115" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00350" }	, "transform": { "type": "literal", "value": "Approximately 90% of the administered drug is metabolized, predominantly by conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring, but also by conversion to more polar products. Known metabolites exert much less pharmacologic effect than minoxidil itself." }	, "mass": { "type": "literal", "value": "209.1277" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00437" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "136.0385" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00443" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "392.1999" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448" }	, "transform": { "type": "literal", "value": "Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H<sup>+</sup>,K<sup>+</sup>)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation." }	, "mass": { "type": "literal", "value": "369.0759" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "309.134" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00475" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "299.0825" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "252.1157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00508" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "352.1221" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00575" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized through minor pathways. The major metabolite, p-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine." }	, "mass": { "type": "literal", "value": "229.0174" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641" }	, "transform": { "type": "literal", "value": "Hepatic, simvastatin is a substrate for CYP3A4." }	, "mass": { "type": "literal", "value": "418.2719" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00654" }	, "transform": { "type": "literal", "value": "Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation." }	, "mass": { "type": "literal", "value": "432.2876" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "370.1537" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00712" }	, "transform": { "type": "literal", "value": "Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4&rsquo;-hydroxy-flurbiprofen. The 4&rsquo;-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation." }	, "mass": { "type": "literal", "value": "244.09" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00722" }	, "transform": { "type": "literal", "value": "Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine" }	, "mass": { "type": "literal", "value": "441.2475" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00726" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "294.2096" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "410.2118" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00744" }	, "transform": { "type": "literal", "value": "Hepatic. Zileuton and its N-dehydroxylated metabolite are oxidatively metabolized by the cytochrome P450 isoenzymes 1A2, 2C9 and 3A4." }	, "mass": { "type": "literal", "value": "236.0619" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00763" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Metabolized rapidly, requiring frequent administration." }	, "mass": { "type": "literal", "value": "114.0252" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00851" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "182.0916" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00863" }	, "transform": { "type": "literal", "value": "Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively." }	, "mass": { "type": "literal", "value": "314.1413" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00897" }	, "transform": { "type": "literal", "value": "Hepatic. Small amounts of unmetabolized triazolam appear in the urine." }	, "mass": { "type": "literal", "value": "342.0439" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00903" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "302.0113" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00926" }	, "transform": { "type": "literal", "value": "Extensively metabolized, with significant first-pass metabolism to the pharmacologically active acid form. Subsequent metabolism results in the inactive 13-cis acid form, chain-shortened breakdown products, and conjugates that are ultimately excreted." }	, "mass": { "type": "literal", "value": "354.2195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00927" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "337.0449" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00959" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "374.2093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00975" }	, "transform": { "type": "literal", "value": "hepatic" }	, "mass": { "type": "literal", "value": "504.3173" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00993" }	, "transform": { "type": "literal", "value": "Primarily converted to the active metabolites 6-mercaptopurine and 6-thioinosinic acid." }	, "mass": { "type": "literal", "value": "277.0382" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01008" }	, "transform": { "type": "literal", "value": "Mainly Hepatic. Busulfan is predominantly metabolized by conjugation with glutathione, both spontaneously and by glutathione S-transferase (GST) catalysis." }	, "mass": { "type": "literal", "value": "246.0232" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01185" }	, "transform": { "type": "literal", "value": "Presence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver" }	, "mass": { "type": "literal", "value": "336.2101" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01197" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "217.0773" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01203" }	, "transform": { "type": "literal", "value": "Not metabolized by the liver and excreted unchanged primarily by the kidneys." }	, "mass": { "type": "literal", "value": "309.194" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01222" }	, "transform": { "type": "literal", "value": "Following absorption, budesonide is subject to high first pass metabolism (80-90%). In vitro experiments in human liver microsomes demonstrate that budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its 2 major metabolites, 6b-hydroxy budesonide and 16a- hydroxy prednisolone. The glucocorticoid activity of these metabolites is negligible (<1/100) in relation to that of the parent compound." }	, "mass": { "type": "literal", "value": "430.2355" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01234" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "392.1999" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01241" }	, "transform": { "type": "literal", "value": "Hepatic. Gemfibrozil mainly undergoes oxidation of a ring methyl group to successively form a hydroxymethyl and a carboxyl metabolite." }	, "mass": { "type": "literal", "value": "250.1569" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01406" }	, "transform": { "type": "literal", "value": "Hepatic, to principal metabolites, ethisterone and 17-hydroxymethylethisterone." }	, "mass": { "type": "literal", "value": "337.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00177" }	, "mass": { "type": "literal", "value": "435.227" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00291" }	, "mass": { "type": "literal", "value": "303.0793" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00695" }	, "mass": { "type": "literal", "value": "330.0077" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00767" }	, "mass": { "type": "literal", "value": "404.2311" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00982" }	, "mass": { "type": "literal", "value": "300.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01216" }	, "mass": { "type": "literal", "value": "372.2777" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00621" }	, "transform": { "type": "literal", "value": "Renal" }	, "mass": { "type": "literal", "value": "306.2195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01020" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "191.043" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB05630" }	, "mass": { "type": "literal", "value": "905.9186" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00411" }	, "mass": { "type": "literal", "value": "182.0822" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00877" }	, "mass": { "type": "literal", "value": "913.5551" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00210" }	, "transform": { "type": "literal", "value": "Metabolized mainly by O-demethylation, hydroxylation and conjugation, and excretion is primarily by the biliary route." }	, "mass": { "type": "literal", "value": "412.2038" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00288" }	, "transform": { "type": "literal", "value": "Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "502.2367" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00302" }	, "transform": { "type": "literal", "value": "Only a small fraction of the drug is metabolized (less than 5%)." }	, "mass": { "type": "literal", "value": "157.1103" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00378" }	, "transform": { "type": "literal", "value": "Metabolism is complete to a 20-dihydrodydrogesterone (DHD) metabolite." }	, "mass": { "type": "literal", "value": "312.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476" }	, "transform": { "type": "literal", "value": "The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine." }	, "mass": { "type": "literal", "value": "333.0954" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00663" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "494.248" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00875" }	, "transform": { "type": "literal", "value": "Mainly hepatic" }	, "mass": { "type": "literal", "value": "434.164" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00947" }	, "transform": { "type": "literal", "value": "Metabolism of fulvestrant appears to involve combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids, including oxidation, aromatic hydroxylation, conjugation with glucuronic acid and/or sulphate at the 2, 3 and 17 positions of the steroid nucleus, and oxidation of the side chain sulphoxide. Identified metabolites are either less active or exhibit similar activity to fulvestrant in antiestrogen models. Studies using human liver preparations and recombinant human enzymes indicate that cytochrome P-450 3A4 (CYP 3A4) is the only P-450 isoenzyme involved in the oxidation of fulvestrant; however, the relative contribution of P-450 and non-P-450 routes in vivo is unknown." }	, "mass": { "type": "literal", "value": "606.3166" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01108" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "329.1991" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01393" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "361.1081" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01567" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "302.0622" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02300" }	, "transform": { "type": "literal", "value": "Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound." }	, "mass": { "type": "literal", "value": "412.2977" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00568" }	, "mass": { "type": "literal", "value": "368.2252" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00693" }	, "mass": { "type": "literal", "value": "332.0685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00958" }	, "mass": { "type": "literal", "value": "371.0445" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01608" }	, "mass": { "type": "literal", "value": "365.1562" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00294" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "324.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00309" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "851.3775" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00374" }	, "transform": { "type": "literal", "value": "Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied." }	, "mass": { "type": "literal", "value": "390.2406" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00380" }	, "transform": { "type": "literal", "value": "Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions." }	, "mass": { "type": "literal", "value": "268.1172" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00413" }	, "transform": { "type": "literal", "value": "No metabolites have been identified in plasma or urine." }	, "mass": { "type": "literal", "value": "211.1143" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00419" }	, "transform": { "type": "literal", "value": "There is no evidence that miglustat is metabolized in humans." }	, "mass": { "type": "literal", "value": "219.1471" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00459" }	, "transform": { "type": "literal", "value": "Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted." }	, "mass": { "type": "literal", "value": "326.1882" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00526" }	, "transform": { "type": "literal", "value": "Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. There is no evidence of cytochrome P450-mediated metabolism in vitro." }	, "mass": { "type": "literal", "value": "397.0601" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00556" }	, "transform": { "type": "literal", "value": "OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids." }	, "mass": { "type": "literal", "value": "187.9872" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00588" }	, "transform": { "type": "literal", "value": "Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man." }	, "mass": { "type": "literal", "value": "500.1844" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00714" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "624.2158" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00789" }	, "transform": { "type": "literal", "value": "No detectable biotransformation or decomposition." }	, "mass": { "type": "literal", "value": "938.2603" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00805" }	, "transform": { "type": "literal", "value": "Hepatic. Cytochrome P4502D is responsible for the 4-hydroxylation of minaprine to 4-hydroxyminaprine." }	, "mass": { "type": "literal", "value": "298.1794" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00873" }	, "transform": { "type": "literal", "value": "The drugs 17 beta-chloromethyl ester function is hydrolyzed to an inactive carboxylic acid moiety." }	, "mass": { "type": "literal", "value": "466.1758" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00905" }	, "transform": { "type": "literal", "value": "Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites." }	, "mass": { "type": "literal", "value": "415.2723" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00922" }	, "transform": { "type": "literal", "value": "Complete metabolism, with some active metabolites (OR-1855 and OR-1896) possibly extending the drug's haemodynamic effects." }	, "mass": { "type": "literal", "value": "280.1073" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00946" }	, "transform": { "type": "literal", "value": "Phenprocoumon is stereoselectively metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites. Cytochrome P450 2C9 is the principal form of human liver P-450 responsible for metabolism." }	, "mass": { "type": "literal", "value": "282.1256" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00957" }	, "transform": { "type": "literal", "value": "GI tract/Hepatic" }	, "mass": { "type": "literal", "value": "369.2304" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00973" }	, "transform": { "type": "literal", "value": "Hepatic, intestinal wall" }	, "mass": { "type": "literal", "value": "409.149" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01001" }	, "transform": { "type": "literal", "value": "Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate." }	, "mass": { "type": "literal", "value": "239.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012" }	, "transform": { "type": "literal", "value": "Metabolism is hepatic by multiple enzymes, primarily CYP3A4, CYP2D6, and CYP1A2. After administration of a 75 mg radiolabeled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolized via: 1) oxidative N-dealkylation to hydrocinnamic acid and hydroxy-hydrocinnamic acid, which are further metabolized via &szlig;-oxidation and glycine conjugation; the oxidative N-dealkylation process also generates metabolites that contain the naphthalene ring; and 2) oxidation of the naphthalene ring on the parent drug to form dihydrodiols, which are further conjugated with glucuronic acid." }	, "mass": { "type": "literal", "value": "357.1704" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01079" }	, "transform": { "type": "literal", "value": "Tegaserod is metabolized mainly via two pathways. The first is a presystemic acid catalyzed hydrolysis in the stomach followed by oxidation and conjugation which produces the main metabolite of tegaserod, 5-methoxyindole-3-carboxylic acid glucuronide. The main metabolite has negligible affinity for 5-HT<sub>4</sub> receptors in vitro. The second metabolic pathway of tegaserod is direct glucuronidation which leads to generation of three isomeric N-glucuronides." }	, "mass": { "type": "literal", "value": "417.2012" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01120" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "323.1304" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01169" }	, "transform": { "type": "literal", "value": "The metabolism of arsenic trioxide involves reduction of pentavalent arsenic to trivalent arsenic by arsenate reductase and methylation of trivalent arsenic to monomethylarsonic acid and monomethylarsonic acid to dimethylarsinic acid by methyltransferases. The main site of methylation reactions appears to be the liver. Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails." }	, "mass": { "type": "literal", "value": "197.8279" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01254" }	, "transform": { "type": "literal", "value": "Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4" }	, "mass": { "type": "literal", "value": "487.1557" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01395" }	, "transform": { "type": "literal", "value": "Hepatic, minor (CYP3A4-mediated)." }	, "mass": { "type": "literal", "value": "366.2195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01624" }	, "transform": { "type": "literal", "value": "The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity." }	, "mass": { "type": "literal", "value": "400.1376" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00307" }	, "mass": { "type": "literal", "value": "348.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00348" }	, "mass": { "type": "literal", "value": "329.0511" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00523" }	, "mass": { "type": "literal", "value": "300.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00725" }	, "mass": { "type": "literal", "value": "369.094" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00761" }	, "mass": { "type": "literal", "value": "73.9326" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00786" }	, "mass": { "type": "literal", "value": "331.2107" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00858" }	, "mass": { "type": "literal", "value": "360.2664" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01435" }	, "mass": { "type": "literal", "value": "188.095" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04552" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "282.0616" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06287" }	, "transform": { "type": "literal", "value": "Hepatic, primarily cytochrome P450 (CYP) 3A4/5." }	, "mass": { "type": "literal", "value": "1029.6025" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00175" }	, "transform": { "type": "literal", "value": "Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4." }	, "mass": { "type": "literal", "value": "424.2461" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00185" }	, "transform": { "type": "literal", "value": "Primarily hepatic, isozymes CYP2D6 and CYP3A4 are responsible for the metabolism of cevimeline. Approximately 44.5% of the drug is converted to cis and trans-sulfoxide, 22.3% to glucuronic acid conjugate, and 4% to N-oxide of cevimeline. Approximately 8% of the trans-sulfoxide metabolite is then converted into the corresponding glucuronic acid conjugate." }	, "mass": { "type": "literal", "value": "199.1031" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00187" }	, "transform": { "type": "literal", "value": "Rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Mainly in red blood cells to a free acid metabolite (with 1/1500 the activity of esmolol) and methanol." }	, "mass": { "type": "literal", "value": "295.1784" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00193" }	, "transform": { "type": "literal", "value": "The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models." }	, "mass": { "type": "literal", "value": "263.1885" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00195" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Approximately 15% of the dose administered is excreted as unchanged drug, the remainder being metabolites whose contribution to the clinical effect is negligible." }	, "mass": { "type": "literal", "value": "307.2147" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00203" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "474.2049" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00216" }	, "transform": { "type": "literal", "value": "In vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite." }	, "mass": { "type": "literal", "value": "382.1715" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00247" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "353.2103" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00252" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "252.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273" }	, "transform": { "type": "literal", "value": "Not extensively metabolized, 70% of the dose is eliminated unchanged in the urine. The other 30% is metabolized hepatically to six metabolites (formed by hydroxylation, hydrolysis, and glucuronidation), none of which constitute more than 5% of an administered dose." }	, "mass": { "type": "literal", "value": "339.0988" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00278" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "508.2468" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00282" }	, "transform": { "type": "literal", "value": "Pamidronate is not metabolized and is exclusively eliminated by renal excretion" }	, "mass": { "type": "literal", "value": "235.0011" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00292" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites." }	, "mass": { "type": "literal", "value": "244.1212" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00296" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "274.2045" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00330" }	, "transform": { "type": "literal", "value": "Hepatic. Up to 15% of administered drug is metabolized to inactive metabolites. The main path of metabolism appears to be an initial oxidation of the alcohol to an aldehydic intermediate, followed by conversion to a dicarboxylic acid." }	, "mass": { "type": "literal", "value": "204.1838" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00333" }	, "transform": { "type": "literal", "value": "Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine." }	, "mass": { "type": "literal", "value": "309.2093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00342" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "471.3137" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343" }	, "transform": { "type": "literal", "value": "Diltiazem is metabolized by and acts as an inhibitor of the CYP3A4 enzyme." }	, "mass": { "type": "literal", "value": "414.1613" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00346" }	, "transform": { "type": "literal", "value": "Hepatic. Alfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylations, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism." }	, "mass": { "type": "literal", "value": "389.2063" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00357" }	, "transform": { "type": "literal", "value": "Hepatic. 34-54% of the administered dose is excreted in the urine as unchanged drug during the first 48 hours, and an additional fraction as an N-acetyl derivative." }	, "mass": { "type": "literal", "value": "232.1212" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00366" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "270.1732" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00379" }	, "transform": { "type": "literal", "value": "Primarily hepatic (85%) via CYP2D6 and CYP1A2 (primarily CYP2D6)." }	, "mass": { "type": "literal", "value": "179.131" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00381" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "408.1452" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00390" }	, "transform": { "type": "literal", "value": "Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation." }	, "mass": { "type": "literal", "value": "780.4296" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00393" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "418.174" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425" }	, "transform": { "type": "literal", "value": "Zolpidem is converted to inactive metabolites in the liver." }	, "mass": { "type": "literal", "value": "307.1685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00449" }	, "transform": { "type": "literal", "value": "Dipivefrin is converted to epinephrine inside the human eye by enzyme hydrolysis." }	, "mass": { "type": "literal", "value": "351.2046" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00454" }	, "transform": { "type": "literal", "value": "Meperidine is metabolized in the liver by hydrolysis to meperidinic acid followed by partial conjugation with glucuronic acid. Meperidine also undergoes N-demethylation to normeperidine, which then undergoes hydrolysis and partial conjugation. Normeperidine is about half as potent as meperidine, but it has twice the CNS stimulation effects." }	, "mass": { "type": "literal", "value": "247.1572" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00470" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "314.2246" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00489" }	, "transform": { "type": "literal", "value": "Sotalol is not metabolized." }	, "mass": { "type": "literal", "value": "272.1195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00492" }	, "transform": { "type": "literal", "value": "Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites." }	, "mass": { "type": "literal", "value": "563.3012" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00504" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "283.1936" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00545" }	, "transform": { "type": "literal", "value": "Hydrolysis by cholinesterases and by liver." }	, "mass": { "type": "literal", "value": "181.0977" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00552" }	, "transform": { "type": "literal", "value": "Primarily hepatic, but only small amounts are metabolized." }	, "mass": { "type": "literal", "value": "268.1172" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00554" }	, "transform": { "type": "literal", "value": "Renal" }	, "mass": { "type": "literal", "value": "331.0627" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00559" }	, "transform": { "type": "literal", "value": "Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound." }	, "mass": { "type": "literal", "value": "551.1839" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00564" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "236.095" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00566" }	, "transform": { "type": "literal", "value": "Chemical analysis of succimer and its metabolites (primarily mixed disulfides of L-cysteine) in the urine showed that succimer was rapidly and extensively metabolized however the specific site of biotransformation is not known." }	, "mass": { "type": "literal", "value": "181.9708" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00574" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "231.1235" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00581" }	, "transform": { "type": "literal", "value": "Lactulose is completely metabolized in the colon by enteric bacteria, and no lactulose is excreted in the feces." }	, "mass": { "type": "literal", "value": "342.1162" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00584" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "376.1998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00585" }	, "transform": { "type": "literal", "value": "Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose)." }	, "mass": { "type": "literal", "value": "331.1137" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00593" }	, "transform": { "type": "literal", "value": "Hepatic, via CYP3A4 and CYP2E1." }	, "mass": { "type": "literal", "value": "141.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00599" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Biotransformation products of thiopental are pharmacologically inactive and mostly excreted in the urine." }	, "mass": { "type": "literal", "value": "242.1089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00604" }	, "transform": { "type": "literal", "value": "Hepatic. Extensively metabolized via cytochrome P450 3A4 enzyme." }	, "mass": { "type": "literal", "value": "465.1831" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00617" }	, "transform": { "type": "literal", "value": "Primarily hepatic (mainly via cytochrome P450 isozyme 2C9), paramethadione is completely demethylated to 5-ethyl-5-methyl-2,4-oxazolidinedione, the active metabolite." }	, "mass": { "type": "literal", "value": "157.0739" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00622" }	, "transform": { "type": "literal", "value": "Nicardipine HCl is metabolized extensively by the liver." }	, "mass": { "type": "literal", "value": "479.2056" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00629" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "230.0126" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00637" }	, "transform": { "type": "literal", "value": "Almost completely metabolized in the liver and primarily excreted in the feces." }	, "mass": { "type": "literal", "value": "458.2482" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00647" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "339.2198" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00652" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "285.2093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00659" }	, "transform": { "type": "literal", "value": "Acamprosate does not undergo metabolism." }	, "mass": { "type": "literal", "value": "181.0409" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00662" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "388.1998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00666" }	, "transform": { "type": "literal", "value": "Enzymatic hydrolysis." }	, "mass": { "type": "literal", "value": "1321.6356" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00682" }	, "transform": { "type": "literal", "value": "Metabolized by hepatic microsomal enzymes." }	, "mass": { "type": "literal", "value": "308.1049" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00683" }	, "transform": { "type": "literal", "value": "Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam, and 4-hydroxymidazolam." }	, "mass": { "type": "literal", "value": "325.0782" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00704" }	, "transform": { "type": "literal", "value": "Hepatic. When administered orally, naltrexone undergoes extensive biotransformation and is metabolized to 6 beta-naltrexol (which may contribute to the therapeutic effect) and other minor metabolites." }	, "mass": { "type": "literal", "value": "341.1627" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00721" }	, "transform": { "type": "literal", "value": "Hydrolysis by plasma esterases to PABA" }	, "mass": { "type": "literal", "value": "236.1525" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00737" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "390.1863" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00751" }	, "transform": { "type": "literal", "value": "Mainly excreted unchanged, less than 10% metabolized." }	, "mass": { "type": "literal", "value": "249.1266" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00752" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "133.0891" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00776" }	, "transform": { "type": "literal", "value": "Oxcarbazepine is completely absorbed and extensively metabolized to its pharmacologically active 10-monohydroxy metabolite (MHD). MHD is metabolized further by conjugation with glucuronic acid." }	, "mass": { "type": "literal", "value": "252.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00780" }	, "transform": { "type": "literal", "value": "Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated." }	, "mass": { "type": "literal", "value": "136.1" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00784" }	, "transform": { "type": "literal", "value": "Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly." }	, "mass": { "type": "literal", "value": "241.1103" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00788" }	, "transform": { "type": "literal", "value": "Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes." }	, "mass": { "type": "literal", "value": "230.0943" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00792" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "255.1735" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00794" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "218.1055" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00807" }	, "transform": { "type": "literal", "value": "Plasma" }	, "mass": { "type": "literal", "value": "294.1943" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00816" }	, "transform": { "type": "literal", "value": "Hepatic and gastric. The major metabolite, orciprenaline-3-0-sulfate, is produced in the gastrointestinal tract. Orciprenaline is not metabolized by catechol-0-methyltransferase nor have glucuronide conjugates been isolated to date." }	, "mass": { "type": "literal", "value": "211.1208" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00830" }	, "transform": { "type": "literal", "value": "Primarily hepatic (via CYP3A and CYP2D6). Resistant to metabolism by monoamine oxidase. Metabolism involves deamination to para-hydroxyamphetamine and phenylacetone; this latter compound is subsequently oxidize to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. Smaller amounts of amphetamine are converted to norephedrine by oxidation." }	, "mass": { "type": "literal", "value": "177.1154" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00832" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "189.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00835" }	, "transform": { "type": "literal", "value": "Hepatic (cytochrome P-450 system), some renal." }	, "mass": { "type": "literal", "value": "318.0732" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00836" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "476.2231" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00848" }	, "transform": { "type": "literal", "value": "Primarily hepatic (extensive) with both active and inactive metabolites." }	, "mass": { "type": "literal", "value": "204.0721" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00865" }	, "transform": { "type": "literal", "value": "Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine." }	, "mass": { "type": "literal", "value": "239.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00867" }	, "transform": { "type": "literal", "value": "Hepatic, by both the mother and fetus" }	, "mass": { "type": "literal", "value": "287.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00870" }	, "transform": { "type": "literal", "value": "Primarily hepatic (mainly via cytochrome P450 isozyme 2C9)." }	, "mass": { "type": "literal", "value": "260.0507" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00880" }	, "transform": { "type": "literal", "value": "Chlorothiazide is not metabolized but is eliminated rapidly by the kidney." }	, "mass": { "type": "literal", "value": "294.9488" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00889" }	, "transform": { "type": "literal", "value": "Primarily hepatic; undergoes N -demethylation and aromatic ring oxidation followed by conjugation. Animal studies suggest that some of the metabolites may have 5-HT 3 receptor antagonist activity." }	, "mass": { "type": "literal", "value": "312.195" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00904" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "293.1528" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00906" }	, "transform": { "type": "literal", "value": "Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450." }	, "mass": { "type": "literal", "value": "375.1327" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00909" }	, "transform": { "type": "literal", "value": "Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2&ndash;sulfamoylacetyl phenol, respectively." }	, "mass": { "type": "literal", "value": "212.0256" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00924" }	, "transform": { "type": "literal", "value": "Extensively metabolized (gastrointestinal and hepatic)." }	, "mass": { "type": "literal", "value": "275.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00934" }	, "transform": { "type": "literal", "value": "Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives." }	, "mass": { "type": "literal", "value": "277.1831" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00938" }	, "transform": { "type": "literal", "value": "Hepatic, metabolized by hydroxylation via CYP3A4" }	, "mass": { "type": "literal", "value": "415.2723" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00949" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "238.0954" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00950" }	, "transform": { "type": "literal", "value": "Approximately 5% of the total dose is metabolized, by cytochrome P450 3A4 and by intestinal microflora." }	, "mass": { "type": "literal", "value": "501.2879" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00961" }	, "transform": { "type": "literal", "value": "Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites." }	, "mass": { "type": "literal", "value": "246.1732" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962" }	, "transform": { "type": "literal", "value": "Zaleplon is primarily metabolized by aldehyde oxidase." }	, "mass": { "type": "literal", "value": "305.1277" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00968" }	, "transform": { "type": "literal", "value": "Hepatic, extensively metabolized. The known urinary metabolites are: a-methyldopa mono-0-sulfate; 3-0-methyl-a-methyldopa; 3,4-dihydroxyphenylacetone; a-methyldopamine; 3-0-methyl-a-methyldopamine and their conjugates." }	, "mass": { "type": "literal", "value": "211.0845" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00991" }	, "transform": { "type": "literal", "value": "Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity." }	, "mass": { "type": "literal", "value": "293.1052" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01018" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "245.0123" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01028" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "163.9607" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01056" }	, "transform": { "type": "literal", "value": "Negligible first pass hepatic degradation. No active metabolites have been found." }	, "mass": { "type": "literal", "value": "192.1263" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01080" }	, "transform": { "type": "literal", "value": "Almost no metabolic transformation. Does not induce the hepatic cytochrome P450 system." }	, "mass": { "type": "literal", "value": "129.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01105" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "279.1754" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01114" }	, "transform": { "type": "literal", "value": "Primarily hepatic via Cytochrome P450 (CYP450) enzymes." }	, "mass": { "type": "literal", "value": "274.1237" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01121" }	, "transform": { "type": "literal", "value": "Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation." }	, "mass": { "type": "literal", "value": "178.0742" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01168" }	, "transform": { "type": "literal", "value": "Procarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO<sub>2</sub> and CH<sub>4</sub> and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine." }	, "mass": { "type": "literal", "value": "221.1528" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182" }	, "transform": { "type": "literal", "value": "Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations." }	, "mass": { "type": "literal", "value": "341.1991" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01186" }	, "transform": { "type": "literal", "value": "Extensively hepatic." }	, "mass": { "type": "literal", "value": "314.1817" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01195" }	, "transform": { "type": "literal", "value": "Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite)." }	, "mass": { "type": "literal", "value": "414.1378" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01219" }	, "transform": { "type": "literal", "value": "Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid." }	, "mass": { "type": "literal", "value": "314.0651" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01221" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "237.092" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01226" }	, "transform": { "type": "literal", "value": "Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality." }	, "mass": { "type": "literal", "value": "1028.561" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01236" }	, "transform": { "type": "literal", "value": "Relatively little biotransformation, only 5% is metabolized by cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. No other metabolic pathways have been identified for sevoflurane." }	, "mass": { "type": "literal", "value": "200.0072" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01244" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "366.2671" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01246" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "298.1504" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01250" }	, "transform": { "type": "literal", "value": "Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)" }	, "mass": { "type": "literal", "value": "302.0539" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01253" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "325.179" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01275" }	, "transform": { "type": "literal", "value": "Hydralazine, when administered orally, undergoes extensive first-pass metabolism by genetic polymorphic acetylation, which is responsible for a threefold range of oral bioavailability. Intravenously administered hydralazine does not undergo first-pass metabolism and, therefore, is not affected by acetylator phenotype. After the drug reaches the systemic circulation, it is combined with endogenous aldehydes and ketones, including pyruvic acid, to form hydrazone metabolites. The active metabolites, hydralazine acetonide hydrazone and hydralazine pyruvate hydrazone, are equipotent with the parent, hydralazine." }	, "mass": { "type": "literal", "value": "160.0749" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01384" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "392.1999" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01388" }	, "transform": { "type": "literal", "value": "The two metabolic pathways that mibefradil undergoes are esterase-catalyzed hydrolysis of the ester side chain (producing an alcohol metabolite) and cytochrome P450 3A4-catalyzed oxidation (that becomes less important during chronic dosing). The pharmacologic effect of the metabolite is approximately 10% of that of the parent mibefradil." }	, "mass": { "type": "literal", "value": "495.2897" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01400" }	, "transform": { "type": "literal", "value": "Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver." }	, "mass": { "type": "literal", "value": "223.1447" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01437" }	, "transform": { "type": "literal", "value": "Hepatic. Glutethimide is almost completely metabolized." }	, "mass": { "type": "literal", "value": "217.1103" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01438" }	, "transform": { "type": "literal", "value": "Likely hepatic but also in other tissues. One of the metabolites is acetaminophen." }	, "mass": { "type": "literal", "value": "213.1014" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01466" }	, "transform": { "type": "literal", "value": "After ingestion, ethylmorphine is converted to morphine in the human liver by the CYP450-isozyme CYP2D6, similarly to codeine." }	, "mass": { "type": "literal", "value": "313.1678" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01588" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "324.1029" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01589" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "386.0268" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01618" }	, "transform": { "type": "literal", "value": "Most likely hepatic. 36 metabolites have been recognized, some of which may be active." }	, "mass": { "type": "literal", "value": "276.1838" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02877" }	, "mass": { "type": "literal", "value": "348.2089" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02998" }	, "mass": { "type": "literal", "value": "284.1776" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03575" }	, "mass": { "type": "literal", "value": "243.1987" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04620" }	, "mass": { "type": "literal", "value": "129.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04690" }	, "mass": { "type": "literal", "value": "348.111" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04805" }	, "mass": { "type": "literal", "value": "823.3541" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04818" }	, "mass": { "type": "literal", "value": "179.1059" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04824" }	, "mass": { "type": "literal", "value": "318.0892" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04830" }	, "mass": { "type": "literal", "value": "157.1327" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04831" }	, "mass": { "type": "literal", "value": "329.952" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04833" }	, "mass": { "type": "literal", "value": "250.1106" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04843" }	, "mass": { "type": "literal", "value": "339.1834" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04844" }	, "mass": { "type": "literal", "value": "317.1991" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00007" }	, "mass": { "type": "literal", "value": "1208.6455" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00104" }	, "mass": { "type": "literal", "value": "1018.4405" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00154" }	, "mass": { "type": "literal", "value": "306.2559" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00212" }	, "mass": { "type": "literal", "value": "630.3451" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00221" }	, "mass": { "type": "literal", "value": "239.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00236" }	, "mass": { "type": "literal", "value": "353.9579" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00245" }	, "mass": { "type": "literal", "value": "307.1936" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00266" }	, "mass": { "type": "literal", "value": "336.0634" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00298" }	, "mass": { "type": "literal", "value": "325.2266" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00376" }	, "mass": { "type": "literal", "value": "301.2406" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00389" }	, "mass": { "type": "literal", "value": "186.0463" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00657" }	, "mass": { "type": "literal", "value": "167.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661" }	, "mass": { "type": "literal", "value": "454.2832" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00697" }	, "mass": { "type": "literal", "value": "253.0189" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00723" }	, "mass": { "type": "literal", "value": "211.1208" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00732" }	, "mass": { "type": "literal", "value": "928.5085" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00748" }	, "mass": { "type": "literal", "value": "290.1186" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00750" }	, "mass": { "type": "literal", "value": "220.1576" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00782" }	, "mass": { "type": "literal", "value": "368.2226" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00795" }	, "mass": { "type": "literal", "value": "398.0685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00804" }	, "mass": { "type": "literal", "value": "309.2668" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00806" }	, "mass": { "type": "literal", "value": "278.1379" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00812" }	, "mass": { "type": "literal", "value": "308.1525" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00841" }	, "mass": { "type": "literal", "value": "301.1678" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00869" }	, "mass": { "type": "literal", "value": "324.0272" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00871" }	, "mass": { "type": "literal", "value": "225.1365" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00901" }	, "mass": { "type": "literal", "value": "461.2202" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00902" }	, "mass": { "type": "literal", "value": "296.1347" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00925" }	, "mass": { "type": "literal", "value": "303.139" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00933" }	, "mass": { "type": "literal", "value": "386.1487" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00935" }	, "mass": { "type": "literal", "value": "260.1889" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00979" }	, "mass": { "type": "literal", "value": "291.1834" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01019" }	, "mass": { "type": "literal", "value": "161.129" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01032" }	, "mass": { "type": "literal", "value": "285.1035" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01086" }	, "mass": { "type": "literal", "value": "165.079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01116" }	, "mass": { "type": "literal", "value": "365.1688" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01144" }	, "mass": { "type": "literal", "value": "303.9146" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01228" }	, "mass": { "type": "literal", "value": "352.2151" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01325" }	, "mass": { "type": "literal", "value": "289.0288" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01338" }	, "mass": { "type": "literal", "value": "602.4771" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01424" }	, "mass": { "type": "literal", "value": "231.1372" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01595" }	, "mass": { "type": "literal", "value": "281.08" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01597" }	, "mass": { "type": "literal", "value": "358.1562" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01599" }	, "mass": { "type": "literal", "value": "516.3096" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01625" }	, "mass": { "type": "literal", "value": "353.2593" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01626" }	, "mass": { "type": "literal", "value": "159.1048" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00189" }	, "transform": { "type": "literal", "value": "About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation." }	, "mass": { "type": "literal", "value": "144.0342" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00248" }	, "transform": { "type": "literal", "value": "Hepatic. Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal." }	, "mass": { "type": "literal", "value": "451.2947" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00293" }	, "transform": { "type": "literal", "value": "Raltitrexed is transported into cells via a reduced folate carrier. Inside the cell it is extensively polyglutamated by the enzyme folyl polyglutamate synthetase to polyglutamate forms." }	, "mass": { "type": "literal", "value": "458.126" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00322" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "246.0652" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00323" }	, "transform": { "type": "literal", "value": "The main metabolic pathway of tolcapone is glucuronidation" }	, "mass": { "type": "literal", "value": "273.0637" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00352" }	, "transform": { "type": "literal", "value": "Hepatic. First converted to 6-thioguanilyic acid (TGMP). TGMP is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) by the same enzymes that metabolize guanine nucleotides." }	, "mass": { "type": "literal", "value": "167.0266" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00356" }	, "transform": { "type": "literal", "value": "Chlorzoxazone is rapidly metabolized in the liver and is excreted in the urine, primarily in a conjugated form as the glucuronide." }	, "mass": { "type": "literal", "value": "168.9931" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00395" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19." }	, "mass": { "type": "literal", "value": "260.1736" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00397" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "151.0997" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00401" }	, "transform": { "type": "literal", "value": "Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4." }	, "mass": { "type": "literal", "value": "388.1634" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00439" }	, "transform": { "type": "literal", "value": "Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23." }	, "mass": { "type": "literal", "value": "459.2421" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00441" }	, "transform": { "type": "literal", "value": "Transformed via nucleoside kinases to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Can also undergo deamination via cytidine deaminase to an inactive uracil metabolite (dFdU)." }	, "mass": { "type": "literal", "value": "263.0718" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00445" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "543.1741" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00473" }	, "transform": { "type": "literal", "value": "Hydrolyzed by plasma esterases to benzoic acid and other derivatives" }	, "mass": { "type": "literal", "value": "261.1729" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00474" }	, "transform": { "type": "literal", "value": "Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity." }	, "mass": { "type": "literal", "value": "262.1317" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00491" }	, "transform": { "type": "literal", "value": "Miglitol is not metabolized in man or in any animal species studied." }	, "mass": { "type": "literal", "value": "207.1107" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00527" }	, "transform": { "type": "literal", "value": "Primarily hepatic." }	, "mass": { "type": "literal", "value": "343.226" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00651" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "254.1015" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00660" }	, "transform": { "type": "literal", "value": "Probably hepatic." }	, "mass": { "type": "literal", "value": "221.1052" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00680" }	, "transform": { "type": "literal", "value": "Hepatic and extensive, to at least 26 metabolites, none accounting for as much as 1% of the administered dose. Two metabolites may be pharmacologically active but are present in extremely small quantities. Moricizine induces its own metabolism (it induces hepatic cytochrome P-450 activity)." }	, "mass": { "type": "literal", "value": "427.1566" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00688" }	, "transform": { "type": "literal", "value": "Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine." }	, "mass": { "type": "literal", "value": "433.2101" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00691" }	, "transform": { "type": "literal", "value": "Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site." }	, "mass": { "type": "literal", "value": "498.2366" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00711" }	, "transform": { "type": "literal", "value": "Partially metabolized to diethylcarbamazine N-oxide." }	, "mass": { "type": "literal", "value": "199.1685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00719" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "290.1783" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00731" }	, "transform": { "type": "literal", "value": "Hepatic, via cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Metabolism is via hydroxylation followed by glucuronidation. The major metabolites have less antidiabetic activity than nateglinide, but the isoprene minor metabolite has antidiabetic activity comparable to that of nateglinide." }	, "mass": { "type": "literal", "value": "317.1991" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00740" }	, "transform": { "type": "literal", "value": "Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450&ndash;dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans." }	, "mass": { "type": "literal", "value": "234.0075" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00754" }	, "transform": { "type": "literal", "value": "Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites." }	, "mass": { "type": "literal", "value": "204.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00757" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "324.1474" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00765" }	, "transform": { "type": "literal", "value": "Little biotransformation, with catechol metabolites accounting for less than 1% of the administered dose." }	, "mass": { "type": "literal", "value": "195.0895" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00768" }	, "transform": { "type": "literal", "value": "The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine." }	, "mass": { "type": "literal", "value": "337.1678" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00774" }	, "transform": { "type": "literal", "value": "Essentially unchanged" }	, "mass": { "type": "literal", "value": "330.9908" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00802" }	, "transform": { "type": "literal", "value": "The liver is the major site of biotransformation." }	, "mass": { "type": "literal", "value": "416.2536" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00810" }	, "transform": { "type": "literal", "value": "The metabolism of biperiden is not completely understood, but does involve hydroxylation." }	, "mass": { "type": "literal", "value": "311.2249" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00814" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "351.0347" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00854" }	, "transform": { "type": "literal", "value": "Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite." }	, "mass": { "type": "literal", "value": "257.178" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00856" }	, "transform": { "type": "literal", "value": "Hepatic. 85% of a dose excreted within 24 hours as the glucuronide metabolite." }	, "mass": { "type": "literal", "value": "202.0397" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00864" }	, "transform": { "type": "literal", "value": "Hepatic, extensive, primarily by CYP3A4. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus." }	, "mass": { "type": "literal", "value": "803.482" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00884" }	, "transform": { "type": "literal", "value": "No evidence found for metabolization of risedronate in humans or mammals" }	, "mass": { "type": "literal", "value": "283.0011" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00899" }	, "transform": { "type": "literal", "value": "By hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases." }	, "mass": { "type": "literal", "value": "376.1998" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00912" }	, "transform": { "type": "literal", "value": "Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an IV or oral dose." }	, "mass": { "type": "literal", "value": "452.2675" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00921" }	, "transform": { "type": "literal", "value": "Hepatic. Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated by cytochrome P-450 3A4 isozyme. Norbuprenorphine, an active metabolite, can further undergo glucuronidation." }	, "mass": { "type": "literal", "value": "467.3036" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00940" }	, "transform": { "type": "literal", "value": "Hepatic, by enzymatic hydrolysis." }	, "mass": { "type": "literal", "value": "340.1913" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00972" }	, "transform": { "type": "literal", "value": "Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system, however the exact cytochrome P450 isoenzyme involved has not been determined. The major metabolite, desmethylazelastine, also has H1-receptor antagonist activity." }	, "mass": { "type": "literal", "value": "381.1608" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00983" }	, "transform": { "type": "literal", "value": "Metabolized primarily by direct glucuronidation at either the phenolic or aliphatic hydroxyl group and O-demethylation followed by glucuronide conjugation at either phenolic hydroxyl groups. Minor pathways involve sulfate conjugation of formoterol and deformylation followed by sulfate conjugation. The most prominent pathway involves direct conjugation at the phenolic hydroxyl group. The second major pathway involves O-demethylation followed by conjugation at the phenolic 2'-hydroxyl group. Four cytochrome P450 isozymes (CYP2D6, CYP2C19, CYP2C9 and CYP2A6) are involved in the O-demethylation of formoterol." }	, "mass": { "type": "literal", "value": "344.1736" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00989" }	, "transform": { "type": "literal", "value": "Rivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis." }	, "mass": { "type": "literal", "value": "250.1681" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00990" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "296.1776" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01002" }	, "transform": { "type": "literal", "value": "Levobupivacaine is extensively metabolized with no unchanged levobupivacaine detected in urine or feces. In vitro studies using [14 C] levobupivacaine showed that CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively. In vivo, the 3-hydroxy levobupivacaine appears to undergo further transformation to glucuronide and sulfate conjugates. Metabolic inversion of levobupivacaine to R(+)-bupivacaine was not evident both in vitro and in vivo." }	, "mass": { "type": "literal", "value": "288.2202" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01031" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "167.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01041" }	, "transform": { "type": "literal", "value": "Thalidomide itself does not appear to be hepatically metabolized to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple metabolites. Thalidomide may be metabolized hepatically by enzymes of the cytochrome P450 enzyme system. The end product of metabolism, phthalic acid, is excreted as a glycine conjugate." }	, "mass": { "type": "literal", "value": "258.0641" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01043" }	, "transform": { "type": "literal", "value": "Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane." }	, "mass": { "type": "literal", "value": "179.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01046" }	, "transform": { "type": "literal", "value": "The results of both human and animal studies indicate that lubiprostone is rapidly and extensively metabolized by 15-position reduction, &alpha;-chain &beta;-oxidation, and &omega;-chain &omega;-oxidation. These biotransformations are not mediated by the hepatic cytochrome P450 system but rather appear to be mediated by the ubiquitously expressed carbonyl reductase. M3, a metabolite of lubiprostone in both humans and animals is formed by the reduction of the carbonyl group at the 15-hydroxy moiety that consists of both &alpha;-hydroxy and &beta;-hydroxy epimers. M3 makes up less than 10% of the dose of radiolabeled lubiprostone." }	, "mass": { "type": "literal", "value": "390.2218" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01084" }	, "transform": { "type": "literal", "value": "Two primary metabolites, 5-hydroxyemedastine and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. The 5'-oxoanalogs of 5-hydroxyemedastine and 6-hydroxy-emedastine and the N-oxide are also formed as minor metabolites." }	, "mass": { "type": "literal", "value": "302.2107" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01122" }	, "transform": { "type": "literal", "value": "Plasma and hepatic" }	, "mass": { "type": "literal", "value": "536.2685" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01133" }	, "transform": { "type": "literal", "value": "In vitro, tiludronic acid is not metabolized in human liver microsomes and hepatocytes. There is no evidence that tiludronate is metabolized in humans." }	, "mass": { "type": "literal", "value": "317.9284" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01157" }	, "transform": { "type": "literal", "value": "Hepatic. Preclinical data strongly suggest that the major metabolic pathway is oxidative O-demethylation, followed by conjugation to either glucuronide or the sulfate." }	, "mass": { "type": "literal", "value": "369.1801" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01173" }	, "transform": { "type": "literal", "value": "Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine." }	, "mass": { "type": "literal", "value": "269.178" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01192" }	, "transform": { "type": "literal", "value": "Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%)." }	, "mass": { "type": "literal", "value": "301.1314" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01202" }	, "transform": { "type": "literal", "value": "The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected." }	, "mass": { "type": "literal", "value": "170.1055" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01209" }	, "transform": { "type": "literal", "value": "Hepatic, via conjugation (glucuronidation)." }	, "mass": { "type": "literal", "value": "245.178" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01217" }	, "transform": { "type": "literal", "value": "Hepatic. Metabolized mainly by N-dealkylation, hydroxylation, and glucuronidation to inactive metabolites. Primary metabolite is an inactive triazole." }	, "mass": { "type": "literal", "value": "293.164" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01230" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "176.0586" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01233" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "299.1401" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01248" }	, "transform": { "type": "literal", "value": "Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites)." }	, "mass": { "type": "literal", "value": "807.3466" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01320" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "362.0668" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01365" }	, "transform": { "type": "literal", "value": "Hepatic, by N-demethylation and then p-hydroxylation." }	, "mass": { "type": "literal", "value": "163.1361" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01434" }	, "transform": { "type": "literal", "value": "Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone." }	, "mass": { "type": "literal", "value": "272.1776" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01579" }	, "transform": { "type": "literal", "value": "Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction" }	, "mass": { "type": "literal", "value": "191.131" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01628" }	, "transform": { "type": "literal", "value": "Hepatic, primarily via CYP3A4." }	, "mass": { "type": "literal", "value": "358.0543" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00040" }	, "mass": { "type": "literal", "value": "3480.6157" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00179" }	, "mass": { "type": "literal", "value": "302.1518" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00232" }	, "mass": { "type": "literal", "value": "358.9568" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00253" }	, "mass": { "type": "literal", "value": "344.2351" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00341" }	, "mass": { "type": "literal", "value": "388.1554" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00383" }	, "mass": { "type": "literal", "value": "344.21" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00436" }	, "mass": { "type": "literal", "value": "421.0378" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00444" }	, "mass": { "type": "literal", "value": "656.1564" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00562" }	, "mass": { "type": "literal", "value": "430.9835" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00600" }	, "mass": { "type": "literal", "value": "200.0837" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00606" }	, "mass": { "type": "literal", "value": "389.0271" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00645" }	, "mass": { "type": "literal", "value": "289.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00703" }	, "mass": { "type": "literal", "value": "236.0038" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00708" }	, "mass": { "type": "literal", "value": "386.2028" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00771" }	, "mass": { "type": "literal", "value": "352.1913" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00914" }	, "mass": { "type": "literal", "value": "205.1327" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00964" }	, "mass": { "type": "literal", "value": "244.0283" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01021" }	, "mass": { "type": "literal", "value": "378.9022" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01034" }	, "mass": { "type": "literal", "value": "223.1208" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01054" }	, "mass": { "type": "literal", "value": "360.1321" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01071" }	, "mass": { "type": "literal", "value": "322.1504" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01148" }	, "mass": { "type": "literal", "value": "391.1784" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01214" }	, "mass": { "type": "literal", "value": "309.194" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01291" }	, "mass": { "type": "literal", "value": "240.1474" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01324" }	, "mass": { "type": "literal", "value": "438.9709" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01380" }	, "mass": { "type": "literal", "value": "402.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01420" }	, "mass": { "type": "literal", "value": "344.2351" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01428" }	, "mass": { "type": "literal", "value": "228.0786" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01486" }	, "mass": { "type": "literal", "value": "151.0997" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01515" }	, "mass": { "type": "literal", "value": "289.1314" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01560" }	, "mass": { "type": "literal", "value": "149.0841" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01619" }	, "mass": { "type": "literal", "value": "261.1518" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00283" }	, "transform": { "type": "literal", "value": "Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation." }	, "mass": { "type": "literal", "value": "343.1703" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00434" }	, "transform": { "type": "literal", "value": "Hepatic (cytochrome P-450 system) and some renal." }	, "mass": { "type": "literal", "value": "287.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00500" }	, "transform": { "type": "literal", "value": "Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin." }	, "mass": { "type": "literal", "value": "257.1052" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00628" }	, "transform": { "type": "literal", "value": "The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine." }	, "mass": { "type": "literal", "value": "314.0458" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00939" }	, "transform": { "type": "literal", "value": "Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid." }	, "mass": { "type": "literal", "value": "295.0167" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00970" }	, "transform": { "type": "literal", "value": "hepatic" }	, "mass": { "type": "literal", "value": "1254.6285" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01081" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "452.2464" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01158" }	, "transform": { "type": "literal", "value": "No metabolites have been identified following administration in man and laboratory animals." }	, "mass": { "type": "literal", "value": "242.0544" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01161" }	, "transform": { "type": "literal", "value": "Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase." }	, "mass": { "type": "literal", "value": "270.1135" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01181" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "260.0248" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00010" }	, "mass": { "type": "literal", "value": "3355.8187" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00035" }	, "mass": { "type": "literal", "value": "1068.427" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00623" }	, "mass": { "type": "literal", "value": "437.1749" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01057" }	, "mass": { "type": "literal", "value": "256.1136" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01284" }	, "mass": { "type": "literal", "value": "2931.5806" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00969" }	, "transform": { "type": "literal", "value": "Hepatic, via microsomal cytochrome P450 (CYP)" }	, "mass": { "type": "literal", "value": "294.1481" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01430" }	, "mass": { "type": "literal", "value": "477.2453" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04836" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "337.2042" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00261" }	, "transform": { "type": "literal", "value": "Extensive, with < 1% recovered unchanged in the urine. Metabolized primarily in the liver by cytochrome P450 1A2 (CYP1A2). Recently, it was found that anagrelide is bio-transformed in humans into two major metabolites (6,7-dichloro-3-hydroxy-1,5 dihydro-imidazo[2,1-b]quinazolin-2-one (BCH24426) and 2-amino-5,6-dichloro-3,4,-dihydroquinazoline (RL603). Whether these metabolites have biological activities that may underlie the mode of action of the parent drug is presently unclear." }	, "mass": { "type": "literal", "value": "254.9966" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00866" }	, "transform": { "type": "literal", "value": "Hepatic. One of the active metabolites, 4-OH-alprenolol, is an active beta-blocker." }	, "mass": { "type": "literal", "value": "249.1729" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01014" }	, "transform": { "type": "literal", "value": "Cleaved in the colon via bacterial azoreduction to 5&ndash;aminosalicylic acid (5&ndash;ASA) and 4&ndash;aminobenzoyl-beta-alanine, the inactive carrier moiety." }	, "mass": { "type": "literal", "value": "357.0961" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01274" }	, "transform": { "type": "literal", "value": "Arformoterol was almost entirely metabolized following oral administration of 35 mcg of radiolabeled arformoterol in eight healthy subjects. Direct conjugation of arformoterol with glucuronic acid was the major metabolic pathway. O-Desmethylation is a secondary route catalyzed by the CYP enzymes CYP2D6 and CYP2C19." }	, "mass": { "type": "literal", "value": "344.1736" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01408" }	, "transform": { "type": "literal", "value": "Hepatic, extensive. Further metabolized to terbutaline by plasma cholinesterase." }	, "mass": { "type": "literal", "value": "403.1874" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01594" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "357.068" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04820" }	, "mass": { "type": "literal", "value": "298.143" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01125" }	, "mass": { "type": "literal", "value": "252.0786" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01282" }	, "mass": { "type": "literal", "value": "987.4848" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01423" }	, "mass": { "type": "literal", "value": "273.0129" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01463" }	, "mass": { "type": "literal", "value": "215.1674" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04837" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "289.1233" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04839" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Cyproterone acetate is metabolized by the CYP3A4 enzyme, forming the active metabolite 15beta-hydroxycyproterone acetate, which retains its antiandrogen activity, but has reduced progestational activity." }	, "mass": { "type": "literal", "value": "374.1649" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04841" }	, "transform": { "type": "literal", "value": "Hepatic, to two metabolites via N-dealylation and hydroxylation." }	, "mass": { "type": "literal", "value": "404.2064" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00050" }	, "transform": { "type": "literal", "value": "In in vitro studies, cetrorelix was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite." }	, "mass": { "type": "literal", "value": "1429.6698" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00223" }	, "transform": { "type": "literal", "value": "Metabolized, primarily in the liver, and then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "410.1905" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00297" }	, "transform": { "type": "literal", "value": "Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4." }	, "mass": { "type": "literal", "value": "288.2202" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00530" }	, "transform": { "type": "literal", "value": "In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1." }	, "mass": { "type": "literal", "value": "393.1689" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00758" }	, "transform": { "type": "literal", "value": "Hepatic, extensive and rapid, by hydrolysis to the main circulating metabolite, a carboxylic acid derivative, which accounts for approximately 85% of the circulating drug-related compounds. A glucuronic acid derivative of the carboxylic acid derivative has also been found in plasma and urine. Neither the parent compound nor the carboxylic acid derivative has a platelet inhibiting effect." }	, "mass": { "type": "literal", "value": "321.059" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00843" }	, "transform": { "type": "literal", "value": "Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 in the liver and also undergoes glucuronidation. The main metabolite, 6-O-desmethyl donepezil, has been reported to inhibit AChE to the same extent as donepezil in vitro." }	, "mass": { "type": "literal", "value": "379.2147" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00998" }	, "transform": { "type": "literal", "value": "In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT<sub>1B/1D</sub> receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown." }	, "mass": { "type": "literal", "value": "243.1372" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01146" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "281.178" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175" }	, "transform": { "type": "literal", "value": "Mainly hepatic. Escitalopram undergoes N-demethylation to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this N-demethylation." }	, "mass": { "type": "literal", "value": "324.1638" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00561" }	, "mass": { "type": "literal", "value": "378.2307" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00963" }	, "mass": { "type": "literal", "value": "333.0001" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01191" }	, "mass": { "type": "literal", "value": "231.1235" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01407" }	, "mass": { "type": "literal", "value": "276.0796" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00152" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "300.0812" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06288" }	, "mass": { "type": "literal", "value": "354.1613" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00762" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "622.2558" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03010" }	, "mass": { "type": "literal", "value": "507.2655" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00017" }	, "transform": { "type": "literal", "value": "Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule." }	, "mass": { "type": "literal", "value": "3429.7133" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00310" }	, "transform": { "type": "literal", "value": "Liver" }	, "mass": { "type": "literal", "value": "338.0128" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00335" }	, "transform": { "type": "literal", "value": "Hepatic (minimal)" }	, "mass": { "type": "literal", "value": "266.163" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00531" }	, "transform": { "type": "literal", "value": "hepatic" }	, "mass": { "type": "literal", "value": "278.0354" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00543" }	, "transform": { "type": "literal", "value": "Amoxapine is almost completely metabolized, producing the major metabolite 8-hydroxyamoxapine." }	, "mass": { "type": "literal", "value": "313.0982" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00868" }	, "transform": { "type": "literal", "value": "Benzonatate is hydrolyzed to para-aminobenzoic acid (PABA) by plasma esterases" }	, "mass": { "type": "literal", "value": "603.3619" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00887" }	, "transform": { "type": "literal", "value": "45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain." }	, "mass": { "type": "literal", "value": "364.1093" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01068" }	, "transform": { "type": "literal", "value": "Hepatic (cytochrome P450, including CYP3A). Biotransformation occurs mainly by reduction of the 7-nitro group to the 4-amino derivative. This derivative can be acetylated, hydroxylated, and glucuronidated." }	, "mass": { "type": "literal", "value": "315.0411" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01427" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "187.0746" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04838" }	, "mass": { "type": "literal", "value": "276.1725" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00672" }	, "mass": { "type": "literal", "value": "276.0335" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00995" }	, "mass": { "type": "literal", "value": "678.1327" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01178" }	, "mass": { "type": "literal", "value": "273.0226" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01223" }	, "mass": { "type": "literal", "value": "420.1982" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00186" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "320.0119" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00214" }	, "transform": { "type": "literal", "value": "Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively." }	, "mass": { "type": "literal", "value": "348.1256" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00231" }	, "transform": { "type": "literal", "value": "Hepatic. Temazepam is completely metabolized through conjugation prior to excretion. The major metabolite is the O-conjugate of temazepam (90%)." }	, "mass": { "type": "literal", "value": "300.0666" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00270" }	, "transform": { "type": "literal", "value": "Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine." }	, "mass": { "type": "literal", "value": "371.1481" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00371" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "218.1267" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00384" }	, "transform": { "type": "literal", "value": "Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels." }	, "mass": { "type": "literal", "value": "253.1076" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00423" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "241.095" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00450" }	, "transform": { "type": "literal", "value": "Extensively metabolized." }	, "mass": { "type": "literal", "value": "379.1696" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00455" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "382.1448" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00461" }	, "transform": { "type": "literal", "value": "Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine." }	, "mass": { "type": "literal", "value": "228.115" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00519" }	, "transform": { "type": "literal", "value": "Cleavage of the ester group of trandolapril, primarily in the liver, is responsible for conversion to trandolaprilat, the active metabolite. Seven other metabolites, resulting primarily from glucuronidation or de-esterification, have been identified." }	, "mass": { "type": "literal", "value": "430.2468" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00555" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "255.0079" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00579" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "284.0716" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00620" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "394.1792" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00648" }	, "transform": { "type": "literal", "value": "Hepatic and renal" }	, "mass": { "type": "literal", "value": "317.9537" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00690" }	, "transform": { "type": "literal", "value": "Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form" }	, "mass": { "type": "literal", "value": "387.1514" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00749" }	, "transform": { "type": "literal", "value": "Etodolac is extensively metabolized in the liver, with renal elimination of etodolac and its metabolites being the primary route of excretion." }	, "mass": { "type": "literal", "value": "287.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00801" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "352.059" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00808" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Indapamide is an extensively metabolized drug with only about 7+ACU- of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration." }	, "mass": { "type": "literal", "value": "365.0601" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00813" }	, "transform": { "type": "literal", "value": "Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system." }	, "mass": { "type": "literal", "value": "336.2202" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00839" }	, "transform": { "type": "literal", "value": "Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%." }	, "mass": { "type": "literal", "value": "311.1304" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00846" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "436.2261" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00874" }	, "transform": { "type": "literal", "value": "Rapidly hydrolyzed (60% within seven hours) and then excreted in the urine, with beta-(2-methoxyphenoxy)-lactic acid as its major urinary metabolite." }	, "mass": { "type": "literal", "value": "198.0892" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00929" }	, "transform": { "type": "literal", "value": "Rapidly de-esterified to misoprostol acid. The de-esterified metabolite undergoes further metabolism by beta and omega oxidation; oxidation is followed by reduction of the ketone to yield prostaglandin F analogs." }	, "mass": { "type": "literal", "value": "382.2719" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00985" }	, "transform": { "type": "literal", "value": "Hepatic (cytochrome P-450 system)." }	, "mass": { "type": "literal", "value": "469.1881" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00996" }	, "transform": { "type": "literal", "value": "All pharmacological actions following gabapentin administration are due to the activity of the parent compound; gabapentin is not appreciably metabolized in humans." }	, "mass": { "type": "literal", "value": "171.1259" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00999" }	, "transform": { "type": "literal", "value": "Hydrochlorothiazide is not metabolized." }	, "mass": { "type": "literal", "value": "296.9645" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01023" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "383.0691" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01042" }	, "transform": { "type": "literal", "value": "Melphalan is not actively metabolised, it spontaneously degrades to mono and dihydroxy products." }	, "mass": { "type": "literal", "value": "304.0745" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01047" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "494.2116" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01067" }	, "transform": { "type": "literal", "value": "Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound." }	, "mass": { "type": "literal", "value": "445.1784" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01075" }	, "transform": { "type": "literal", "value": "Hepatic and renal" }	, "mass": { "type": "literal", "value": "255.1623" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01077" }	, "transform": { "type": "literal", "value": "Not metabolized." }	, "mass": { "type": "literal", "value": "249.9384" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01206" }	, "transform": { "type": "literal", "value": "Hepatic. Rapid and complete, with active metabolites." }	, "mass": { "type": "literal", "value": "233.0931" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01215" }	, "transform": { "type": "literal", "value": "Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A)." }	, "mass": { "type": "literal", "value": "294.0672" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01337" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "730.292" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01399" }	, "transform": { "type": "literal", "value": "Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body." }	, "mass": { "type": "literal", "value": "258.0528" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01623" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "443.1701" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB05246" }	, "mass": { "type": "literal", "value": "203.0946" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00347" }	, "mass": { "type": "literal", "value": "143.0582" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00418" }	, "mass": { "type": "literal", "value": "238.1317" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00524" }	, "mass": { "type": "literal", "value": "365.0601" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00532" }	, "mass": { "type": "literal", "value": "218.1055" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00809" }	, "mass": { "type": "literal", "value": "284.1525" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00226" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "524.2628" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00800" }	, "transform": { "type": "literal", "value": "Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Methylation, glucuronidation, and sulfation are the main routes of conjugation." }	, "mass": { "type": "literal", "value": "401.07" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00974" }	, "transform": { "type": "literal", "value": "Almost none of the compound is metabolized." }	, "mass": { "type": "literal", "value": "374.0015" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00986" }	, "mass": { "type": "literal", "value": "397.1253" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00308" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Eight metabolites of ibutilide were detected in metabolic profiling of urine. These metabolites are thought to be formed primarily by o-oxidation followed by sequential b-oxidation of the heptyl side chain of ibutilide. Of the eight metabolites, only the o-hydroxy metabolite possesses class III electrophysiologic properties similar to that of ibutilide in an in vitro isolated rabbit myocardium model." }	, "mass": { "type": "literal", "value": "884.5003" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00429" }	, "transform": { "type": "literal", "value": "Metabolized in the lungs and liver. Metabolites are excreted in urine." }	, "mass": { "type": "literal", "value": "489.3302" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00462" }	, "transform": { "type": "literal", "value": "Little is known about the fate and excretion of methscopolamine." }	, "mass": { "type": "literal", "value": "397.0889" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00565" }	, "transform": { "type": "literal", "value": "The degradation of cisatracurium is largely independent of liver metabolism. Results from in vitro experiments suggest that cisatracurium undergoes Hofmann elimination (a pH and temperature-dependent chemical process) to form laudanosine and the monoquaternary acrylate metabolite. The monoquaternary acrylate undergoes hydrolysis by non-specific plasma esterases to form the monoquaternary alcohol metabolite. The monoquaternary alcohol metabolite can also undergo Hofmann elimination but at a much slower rate than cisatracurium. Laudanosine is further metabolized to desmethyl metabolites which are conjugated with glucuronic acid and excreted in the urine." }	, "mass": { "type": "literal", "value": "1242.5004" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00953" }	, "transform": { "type": "literal", "value": "Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma." }	, "mass": { "type": "literal", "value": "391.2008" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01135" }	, "transform": { "type": "literal", "value": "In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile." }	, "mass": { "type": "literal", "value": "1104.4728" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00068" }	, "mass": { "type": "literal", "value": "19867.2792" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00416" }	, "mass": { "type": "literal", "value": "906.1602" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00728" }	, "mass": { "type": "literal", "value": "608.3189" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00944" }	, "mass": { "type": "literal", "value": "714.2355" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00611" }	, "transform": { "type": "literal", "value": "Extensively metabolized in the liver. The pharmacological activity of butorphanol metabolites has not been studied in humans; in animal studies, butorphanol metabolites have demonstrated some analgesic activity." }	, "mass": { "type": "literal", "value": "477.2363" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00258" }	, "mass": { "type": "literal", "value": "157.9892" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00326" }	, "mass": { "type": "literal", "value": "490.0847" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01010" }	, "mass": { "type": "literal", "value": "201.092" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00209" }	, "transform": { "type": "literal", "value": "Not fully defined" }	, "mass": { "type": "literal", "value": "427.1914" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00275" }	, "transform": { "type": "literal", "value": "Olmesartan is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. There is virtually no further metabolism of olmesartan." }	, "mass": { "type": "literal", "value": "558.2227" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00349" }	, "transform": { "type": "literal", "value": "Hepatic. Clobazam has two major metabolites: N-desmethyl-clobazam and 4'-hydroxyclobazam, the former of which is active. The demethylation is facilitated by CYP2C19, CYP3A4, and CYP2B6 and the 4'-hydroxyclobazam by CYP2C18 and CYP2C19." }	, "mass": { "type": "literal", "value": "300.0666" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00650" }	, "transform": { "type": "literal", "value": "Hepatic and intestinal mucosal, the main metabolite being the active 5-methyltetrahydrofolate. Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme." }	, "mass": { "type": "literal", "value": "511.1128" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00885" }	, "transform": { "type": "literal", "value": "Hepatic (Ophthalmic)" }	, "mass": { "type": "literal", "value": "266.0318" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01107" }	, "transform": { "type": "literal", "value": "Hepatic. Methyprylon is almost completely metabolized." }	, "mass": { "type": "literal", "value": "183.1259" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01544" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "313.0863" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01558" }	, "transform": { "type": "literal", "value": "Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes)." }	, "mass": { "type": "literal", "value": "317.0164" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00391" }	, "mass": { "type": "literal", "value": "341.1409" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00392" }	, "mass": { "type": "literal", "value": "348.1427" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00597" }	, "mass": { "type": "literal", "value": "559.1277" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01078" }	, "mass": { "type": "literal", "value": "942.4824" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06262" }	, "transform": { "type": "literal", "value": "Droxidopa is metabolized by aromatic L-amino acid decarboxylase" }	, "mass": { "type": "literal", "value": "213.0637" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00242" }	, "transform": { "type": "literal", "value": "Metabolized in all cells with deoxycytidine kinase activity to 2-chloro-2'-deoxyadenosine-5'-triphosphate" }	, "mass": { "type": "literal", "value": "285.0629" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00522" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine." }	, "mass": { "type": "literal", "value": "404.1372" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00920" }	, "transform": { "type": "literal", "value": "Primarily hepatic. The main metabolite found in both plasma and urine is the inactive ketotifen-N-glucuronide. Nor-ketotifen, the N-demethylated metabolite, and the 10-alpha-hydroxyl derivative are the only other metabolites detectable in human urine." }	, "mass": { "type": "literal", "value": "425.1297" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01013" }	, "transform": { "type": "literal", "value": "Metabolized, primarily in the liver, and then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "466.1922" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01160" }	, "transform": { "type": "literal", "value": "Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver." }	, "mass": { "type": "literal", "value": "475.3145" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01198" }	, "transform": { "type": "literal", "value": "Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance." }	, "mass": { "type": "literal", "value": "388.1051" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01559" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "318.0594" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01600" }	, "transform": { "type": "literal", "value": "Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites." }	, "mass": { "type": "literal", "value": "260.0507" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00265" }	, "mass": { "type": "literal", "value": "203.131" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00324" }	, "mass": { "type": "literal", "value": "376.205" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00345" }	, "mass": { "type": "literal", "value": "216.0511" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00463" }	, "mass": { "type": "literal", "value": "198.1004" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00699" }	, "mass": { "type": "literal", "value": "483.1158" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01578" }	, "mass": { "type": "literal", "value": "788.8541" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04878" }	, "transform": { "type": "literal", "value": "Little metabolism occurs and no metabolites have as yet been identified." }	, "mass": { "type": "literal", "value": "267.1318" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00183" }	, "transform": { "type": "literal", "value": "Primarily hepatic" }	, "mass": { "type": "literal", "value": "767.3312" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00538" }	, "transform": { "type": "literal", "value": "None detected" }	, "mass": { "type": "literal", "value": "662.1547" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01249" }	, "transform": { "type": "literal", "value": "Excreted unchanged" }	, "mass": { "type": "literal", "value": "1549.7133" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04890" }	, "mass": { "type": "literal", "value": "546.1591" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01436" }	, "mass": { "type": "literal", "value": "400.3341" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04711" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "1139.512" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00240" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "520.2228" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00469" }	, "transform": { "type": "literal", "value": "Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam)." }	, "mass": { "type": "literal", "value": "337.0191" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00591" }	, "transform": { "type": "literal", "value": "Primarily hepatic, corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "452.201" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "273.0823" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01025" }	, "transform": { "type": "literal", "value": "Metabolized to hydroxylated and conjugated metabolites." }	, "mass": { "type": "literal", "value": "298.0954" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00569" }	, "mass": { "type": "literal", "value": "1726.7708" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01184" }	, "mass": { "type": "literal", "value": "425.1619" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01362" }	, "mass": { "type": "literal", "value": "820.8803" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04898" }	, "transform": { "type": "literal", "value": "Hepatic. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen)." }	, "mass": { "type": "literal", "value": "473.2638" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00287" }	, "transform": { "type": "literal", "value": "Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the &alpha;(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond." }	, "mass": { "type": "literal", "value": "500.2386" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00317" }	, "transform": { "type": "literal", "value": "Primarily hepatic via CYP3A4. Three sites of biotransformation have been identified: metabolism of the N-propoxymorpholino-group, demethylation of the methoxy-substituent on the quinazoline, and oxidative defluorination of the halogenated phenyl group." }	, "mass": { "type": "literal", "value": "446.1521" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00820" }	, "transform": { "type": "literal", "value": "Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite. The catechol metabolite undergoes extensive methylation and glucuronidation to form the methylcatechol and methylcatechol glucuronide conjugate, respectively. In vitro data suggests the metabolites are not expected to be pharmacologically active at observed metabolite concentrations." }	, "mass": { "type": "literal", "value": "389.1376" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01166" }	, "transform": { "type": "literal", "value": "Hepatic. Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine. Two metabolites are active, with one metabolite appearing to account for at least 50% of the pharmacologic (PDE III inhibition) activity after administration of cilostazol." }	, "mass": { "type": "literal", "value": "369.2165" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00747" }	, "mass": { "type": "literal", "value": "437.1049" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01073" }	, "mass": { "type": "literal", "value": "365.0537" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01303" }	, "mass": { "type": "literal", "value": "283.1644" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00838" }	, "transform": { "type": "literal", "value": "Metabolized, primarily in the liver, and then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "494.2235" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00320" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "679.2676" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01030" }	, "transform": { "type": "literal", "value": "Topotecan undergoes a reversible pH dependent hydrolysis of its lactone moiety; it is the lactone form that is pharmacologically active." }	, "mass": { "type": "literal", "value": "457.1404" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01085" }	, "transform": { "type": "literal", "value": "Possibly occurs at the neuronal synapses and in the plasma" }	, "mass": { "type": "literal", "value": "244.0979" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06689" }	, "mass": { "type": "literal", "value": "343.3086" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00271" }	, "mass": { "type": "literal", "value": "613.7696" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00483" }	, "mass": { "type": "literal", "value": "891.1769" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01113" }	, "mass": { "type": "literal", "value": "375.1237" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01199" }	, "mass": { "type": "literal", "value": "770.2948" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289" }	, "transform": { "type": "literal", "value": "Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs)." }	, "mass": { "type": "literal", "value": "291.139" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00891" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "249.0572" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01171" }	, "transform": { "type": "literal", "value": "Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6." }	, "mass": { "type": "literal", "value": "268.0979" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01247" }	, "transform": { "type": "literal", "value": "Hepatic and rapid (by oxidation)." }	, "mass": { "type": "literal", "value": "231.1008" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04825" }	, "mass": { "type": "literal", "value": "329.2144" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00311" }	, "mass": { "type": "literal", "value": "258.0133" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00724" }	, "mass": { "type": "literal", "value": "240.1375" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01251" }	, "mass": { "type": "literal", "value": "527.209" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00054" }	, "transform": { "type": "literal", "value": "Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production" }	, "mass": { "type": "literal", "value": "47580.23" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00106" }	, "transform": { "type": "literal", "value": "<i>In vitro</i> hepatocyte (rat, monkey, human) studies and <i>in vivo</i> studies in rats and monkeys showed that the major metabolites of abarelix were formed via hydrolysis of peptide bonds. No significant oxidative or conjugated metabolites of abarelix were found either <i>in vitro</i> or <i>in vivo</i>. There is no evidence of cytochrome P-450 involvement in the metabolism of abarelix." }	, "mass": { "type": "literal", "value": "1414.6841" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00230" }	, "transform": { "type": "literal", "value": "Negligible" }	, "mass": { "type": "literal", "value": "159.1259" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00385" }	, "transform": { "type": "literal", "value": "Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol." }	, "mass": { "type": "literal", "value": "723.2139" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402" }	, "transform": { "type": "literal", "value": "Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation." }	, "mass": { "type": "literal", "value": "388.1051" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00409" }	, "transform": { "type": "literal", "value": "No active metabolites" }	, "mass": { "type": "literal", "value": "370.0892" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00546" }	, "transform": { "type": "literal", "value": "Hepatic. The main metabolite is N-desmethyladinazolam. The other two metabolites are alpha-hydroxyalprazolam and estazolam." }	, "mass": { "type": "literal", "value": "351.1251" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00580" }	, "transform": { "type": "literal", "value": "Hepatic (involves CYP3A4 and 2C9)" }	, "mass": { "type": "literal", "value": "314.0725" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00980" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "259.1572" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01088" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain." }	, "mass": { "type": "literal", "value": "360.2301" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01353" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "212.1161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04842" }	, "mass": { "type": "literal", "value": "475.2435" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00009" }	, "mass": { "type": "literal", "value": "58969.675" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00022" }	, "mass": { "type": "literal", "value": "19256.7431" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00052" }	, "mass": { "type": "literal", "value": "22111.0409" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00053" }	, "mass": { "type": "literal", "value": "55562.1608" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00069" }	, "mass": { "type": "literal", "value": "19551.846" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00092" }	, "mass": { "type": "literal", "value": "72414.14" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00105" }	, "mass": { "type": "literal", "value": "19256.7431" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00488" }	, "mass": { "type": "literal", "value": "210.1593" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00587" }	, "mass": { "type": "literal", "value": "412.1821" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00918" }	, "mass": { "type": "literal", "value": "469.1883" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00673" }	, "transform": { "type": "literal", "value": "Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma." }	, "mass": { "type": "literal", "value": "534.1502" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00913" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "352.2151" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03880" }	, "mass": { "type": "literal", "value": "477.1756" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04812" }	, "mass": { "type": "literal", "value": "301.0506" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00026" }	, "mass": { "type": "literal", "value": "17246.4608" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00047" }	, "transform": { "type": "literal", "value": "Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process." }	, "mass": { "type": "literal", "value": "6058.8184" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00188" }	, "transform": { "type": "literal", "value": "In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2, while bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites which are inactive as 26S proteasome inhibitors." }	, "mass": { "type": "literal", "value": "384.1969" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00241" }	, "transform": { "type": "literal", "value": "Hepatic, although most of the dose is eliminated via the kidney (59 to 88%). Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%)." }	, "mass": { "type": "literal", "value": "224.1161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00821" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "273.0557" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01188" }	, "transform": { "type": "literal", "value": "Glucuronidation is the main metabolic pathway of ciclopirox." }	, "mass": { "type": "literal", "value": "207.1259" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01237" }	, "transform": { "type": "literal", "value": "Hepatic (cytochrome P-450 system); some renal." }	, "mass": { "type": "literal", "value": "369.0495" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01258" }	, "transform": { "type": "literal", "value": "Hepatic. About one-fourth of the absorbed dose appears in the urine as parent drug. How much of the absorbed dose is metabolized is unknown. Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP 3A4." }	, "mass": { "type": "literal", "value": "551.3934" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01277" }	, "transform": { "type": "literal", "value": "Both the liver and the kidney have been shown to metabolize IGF-1." }	, "mass": { "type": "literal", "value": "7643.5862" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00006" }	, "mass": { "type": "literal", "value": "2178.9858" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00016" }	, "mass": { "type": "literal", "value": "18224.5242" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00403" }	, "mass": { "type": "literal", "value": "1351.4485" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01243" }	, "mass": { "type": "literal", "value": "212.9748" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01272" }	, "mass": { "type": "literal", "value": "105270.8023" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01281" }	, "mass": { "type": "literal", "value": "84342.0374" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01564" }	, "mass": { "type": "literal", "value": "316.2402" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00001" }	, "transform": { "type": "literal", "value": "Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug." }	, "mass": { "type": "literal", "value": "6958.962" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00074" }	, "transform": { "type": "literal", "value": "Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes, or by human antimurine antibody production" }	, "mass": { "type": "literal", "value": "144031.1268" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00111" }	, "transform": { "type": "literal", "value": "Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes." }	, "mass": { "type": "literal", "value": "144031.1268" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00496" }	, "transform": { "type": "literal", "value": "Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4." }	, "mass": { "type": "literal", "value": "426.2307" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00547" }	, "transform": { "type": "literal", "value": "Metabolized, primarily in the liver, and then excreted by the kidneys." }	, "mass": { "type": "literal", "value": "376.205" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00631" }	, "transform": { "type": "literal", "value": "Clofarabine is sequentially metabolized intracellularly to the 5&rsquo;-monophosphate metabolite by deoxycytidine kinase and mono- and di-phosphokinases to the active 5&rsquo;-triphosphate metabolite. Clofarabine has high affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine." }	, "mass": { "type": "literal", "value": "303.0534" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00642" }	, "transform": { "type": "literal", "value": "Metabolized by Cytochrome P450 Enzymes" }	, "mass": { "type": "literal", "value": "471.1131" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00720" }	, "transform": { "type": "literal", "value": "Clodronate is not metabolized in humans." }	, "mass": { "type": "literal", "value": "243.886" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00937" }	, "transform": { "type": "literal", "value": "Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion." }	, "mass": { "type": "literal", "value": "241.1233" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01126" }	, "transform": { "type": "literal", "value": "Hepatic. Extensively metabolized." }	, "mass": { "type": "literal", "value": "528.2211" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01262" }	, "transform": { "type": "literal", "value": "The exact route of elimination and metabolic fate of decitabine is not known in humans.  One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood." }	, "mass": { "type": "literal", "value": "228.0859" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01283" }	, "transform": { "type": "literal", "value": "Hepatic oxidation and hydroxylation via CYP2C9. Three major metabolites have been identified in plasma: 4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib, and 4'-hydroxy-5-carboxy-lumiracoxib." }	, "mass": { "type": "literal", "value": "293.0619" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01609" }	, "transform": { "type": "literal", "value": "Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion." }	, "mass": { "type": "literal", "value": "373.1063" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00004" }	, "mass": { "type": "literal", "value": "57605.128" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00967" }	, "mass": { "type": "literal", "value": "310.1237" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01134" }	, "mass": { "type": "literal", "value": "414.277" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01260" }	, "mass": { "type": "literal", "value": "416.2199" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04880" }	, "transform": { "type": "literal", "value": "Hepatic oxidation" }	, "mass": { "type": "literal", "value": "248.0619" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00736" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "367.0967" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01083" }	, "transform": { "type": "literal", "value": "Metabolized primarily within the gastrointestinal wall forming relatively inactive metabolites. Metabolites M1 (4-member lactone ring hydrolyzed) and M3 (M1 with N-formyl leucine moiety cleaved) accounted for approximately 42% of total radioactivity in plasma. M1 and M3 have an open beta-lactone ring and extremely weak lipase inhibitory activity (1000- and 2500-fold less than orlistat, respectively)." }	, "mass": { "type": "literal", "value": "495.3924" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01259" }	, "transform": { "type": "literal", "value": "Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma." }	, "mass": { "type": "literal", "value": "942.1841" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01288" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "303.1471" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00093" }	, "mass": { "type": "literal", "value": "1039.4368" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00824" }	, "mass": { "type": "literal", "value": "194.0804" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01276" }	, "mass": { "type": "literal", "value": "4184.0273" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01613" }	, "mass": { "type": "literal", "value": "301.9982" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00014" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "1268.6414" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00046" }	, "transform": { "type": "literal", "value": "Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process." }	, "mass": { "type": "literal", "value": "5803.6376" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00667" }	, "transform": { "type": "literal", "value": "Primarily hepatic. Histamine is rapidly metabolized by methylation and oxidation. Methylation involves ring methylation and catalyzation by the enzyme histamine-N-methyltransferase, producing N-methylhistamine, which is mostly converted to N-methyl imidazole acetic acid. 2 to 3% excreted as free histamine, 4 to 8% as N-methylhistamine, 42 to 47% as N-methyl imidazole acetic acid, 9 to 11% as imidazole acetic acid, and 16 to 23% as imidazole acetic acid riboside" }	, "mass": { "type": "literal", "value": "307.0334" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01170" }	, "transform": { "type": "literal", "value": "Guanethidine is converted by the liver to three metabolites, which are excreted in the urine. The metabolites are pharmacologically less active than the parent compound." }	, "mass": { "type": "literal", "value": "296.1518" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00596" }	, "mass": { "type": "literal", "value": "484.1828" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00941" }	, "mass": { "type": "literal", "value": "660.1715" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01342" }	, "mass": { "type": "literal", "value": "416.2437" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00480" }	, "transform": { "type": "literal", "value": "The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. The process exceeds the glomerular filtration rate and therefore is partially or entirely active." }	, "mass": { "type": "literal", "value": "259.0957" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00090" }	, "mass": { "type": "literal", "value": "82067.1507" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01433" }	, "mass": { "type": "literal", "value": "353.2355" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04899" }	, "transform": { "type": "literal", "value": "Nesiritide undergoes proteolytic cleavage of the peptide by endopeptidases, such as neutral endopeptidase, which are present on the vascular lumenal surface." }	, "mass": { "type": "literal", "value": "3461.7377" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00486" }	, "transform": { "type": "literal", "value": "Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted." }	, "mass": { "type": "literal", "value": "372.2664" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01024" }	, "transform": { "type": "literal", "value": "Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state." }	, "mass": { "type": "literal", "value": "320.126" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267" }	, "transform": { "type": "literal", "value": "Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission." }	, "mass": { "type": "literal", "value": "426.2067" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01280" }	, "transform": { "type": "literal", "value": "The principal route of metabolism for nelarabine is O-demethylation by adenosine deaminase to form ara-G, which undergoes hydrolysis to form guanine. In addition, some nelarabine is hydrolyzed to form methylguanine, which is O-demethylated to form guanine. Guanine is N-deaminated to form xanthine, which is further oxidized to yield uric acid. Ring opening of uric acid followed by further oxidation results in the formation of allantoin." }	, "mass": { "type": "literal", "value": "297.1073" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00038" }	, "mass": { "type": "literal", "value": "19035.5679" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00039" }	, "mass": { "type": "literal", "value": "16400.3409" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04834" }	, "transform": { "type": "literal", "value": "Hydrolyzed to active metabolites (Cytochrome P450 system is not involved)." }	, "mass": { "type": "literal", "value": "676.3815" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00337" }	, "transform": { "type": "literal", "value": "Metabolized by the CYP3A sub-family of metabolizing enzymes." }	, "mass": { "type": "literal", "value": "809.4481" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00837" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "334.0884" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00896" }	, "transform": { "type": "literal", "value": "Undergoes extensive metabolism. Following intravenous administration of radiolabeled rimexolone in rats, more than 80% of the dose was excreted in the feces as rimexolone and metabolites. Metabolites have been shown to be either less active than rimexolone or inactive in human glucocorticoid receptor binding assays." }	, "mass": { "type": "literal", "value": "370.2508" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01130" }	, "transform": { "type": "literal", "value": "Primarily in skin" }	, "mass": { "type": "literal", "value": "488.241" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01278" }	, "transform": { "type": "literal", "value": "Metabolized primarily by the kidneys." }	, "mass": { "type": "literal", "value": "3946.9207" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00015" }	, "mass": { "type": "literal", "value": "39546.0247" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01207" }	, "mass": { "type": "literal", "value": "366.1191" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01270" }	, "mass": { "type": "literal", "value": "48349.6111" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06285" }	, "transform": { "type": "literal", "value": "Hepatic" }	, "mass": { "type": "literal", "value": "4115.1309" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02546" }	, "transform": { "type": "literal", "value": "The major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by \uFFFD\uFFFD-oxidation. Human serum levels of two metabolites, O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP)." }	, "mass": { "type": "literal", "value": "264.1474" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04894" }	, "mass": { "type": "literal", "value": "1130.483" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04900" }	, "mass": { "type": "literal", "value": "3106.5041" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00031" }	, "mass": { "type": "literal", "value": "58703.4783" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00853" }	, "mass": { "type": "literal", "value": "194.0552" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00063" }	, "transform": { "type": "literal", "value": "No major metabolites have been detected in human plasma. Deamidated eptifibatide and other, more polar metabolites have been detected in urine." }	, "mass": { "type": "literal", "value": "831.3156" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00112" }	, "transform": { "type": "literal", "value": "Most likely removed by opsonization via the reticuloendothelial system when bound to endothelial cells, or by human antimurine antibody production" }	, "mass": { "type": "literal", "value": "149104.8407" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00162" }	, "transform": { "type": "literal", "value": "Hepatic. Retinol is conjugated with glucuronic acid; the B-glucuronide undergoes enterohepatic circulation and oxidation to retinol and retinoic acid. Retinoic acid undergoes decarboxylation and conjugation with glucuronic acid." }	, "mass": { "type": "literal", "value": "286.2297" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01418" }	, "transform": { "type": "literal", "value": "Hepatic." }	, "mass": { "type": "literal", "value": "353.0899" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00219" }	, "mass": { "type": "literal", "value": "427.1722" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00306" }	, "mass": { "type": "literal", "value": "224.1161" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00729" }	, "mass": { "type": "literal", "value": "389.1661" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01279" }	, "mass": { "type": "literal", "value": "55833.1016" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01614" }	, "mass": { "type": "literal", "value": "326.1453" }},
    { "drug": { "type": "uri", "value": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02638" }	, "mass": { "type": "literal", "value": "1226.4961" }} ] } }